CD3-specific de-immunized antibodies

By modifying the complementary determination region of CD3-specific antibodies, its immunogenicity in humans is reduced, and the problem of dose-limiting toxicity and immune response in CD3-targeted therapy is solved, achieving safer and more effective therapeutic effects .

CN118922448APending Publication Date: 2024-11-08MORFOZIS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029580.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-22
Filing Date
2023-03-21
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing CD3-targeted therapies are limited in their use due to the problems of dose-limiting toxicity and triggering immune responses, especially due to the side effects and inflammatory responses caused by the ability of CD3 antibodies to stimulate T cells.

Method used

An optimized whole-human CD3-specific antibody has been developed, which is altered in the complementary determining region (CDR) to reduce the risk of immunogenicity and immune response in humans, through specific amino acid sequence variants and structural modifications, Reduces the presence of T cell epitope, thereby reducing the possibility of binding to HLA protein.

Benefits of technology

It effectively reduces the risk of triggering an immune response in humans, reduces the occurrence of side effects, improves the stability and productivity of antibodies, while maintaining a high affinity for CD3, and enhancing its safety and effectiveness in treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005054998560000111
    Figure BDA0005054998560000111
  • Figure BDA0005054998560000113
    Figure BDA0005054998560000113
  • Figure BDA0005054998560000114
    Figure BDA0005054998560000114
Patent Text Reader

Abstract

The present invention provides affinity optimized and de-immunized human antibodies that specifically bind to CD3. The disclosure also provides bispecific antibodies comprising optimized human antibodies, e.g., for activating T cells. The invention also relates to methods of producing human antibodies and methods of using them to treat diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to fully human antibodies that bind to CD3, including structurally modified variants thereof, which have a reduced likelihood of binding to HLA proteins and thus, once administered, have a reduced risk of eliciting an immune response in humans. The present invention also provides bispecific antibodies employing the CD3-specific antibodies disclosed herein, methods of producing such antibodies, and methods of using them to treat diseases (e.g., treat cancer). Background Art

[0002] CD3 (cluster of differentiation 3) is a protein complex composed of at least four invariant polypeptide chains, which are non-covalently bound to the T cell receptor (TCR) on the surface of T cells, commonly referred to as the CD3 antigen complex. After the antigen binds to the T cell receptor, the CD3 antigen complex plays an important role in T cell activation. CD3 has been widely explored as a drug target. The therapeutic concept of bispecific antibodies based on targeting CD3 relies on the simultaneous binding of cell surface antigens on tumor cells and CD3 present on cytotoxic T cells, with the aim of directly killing tumor cells with the bound cytotoxic T cells (Miller and Kontermann, Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 2010, 24 (2): 89-98).

[0003] A major problem with CD3 targeted therapy is its dose-limiting toxicity, which is caused by off-target T cell activation. Such toxicity is essentially driven by the inherent ability of CD3 antibodies to stimulate T cells, regardless of whether target cells are present. In fact, many side effects observed in CD3-based antibody therapies appear to be related to abnormal T cell function, such as related cytokine production, which may lead to toxic cytokine release syndrome. Therefore, in order to reduce such toxicity, it is now well established to bind to CD3 present on T cells in a monovalent manner and use an antibody skeleton that lacks the ability to bind to Fc receptors on accessory cells (such as monocytes, B cells, and NK cells). This approach avoids cross-linking of CD3 complexes present on T cells and their subsequent activation.

[0004] A large number of antibodies that bind to CD3 have been described in the art. This includes antibodies of rodent origin, such as OKT-3 (Kung P. et al., Science, 1979 Oct 19; 206 (4416): 347-9) or SP34 (Yoshino N. et al., Exp. Anim 49: 97-110, 2000; Conrad ML. et al., Cytometry 71A: 925-33, 2007), and humanized derivatives thereof. In addition, a large number of human antibodies or humanized antibodies with CD3 specificity generated de novo have been described in the art. Because they are derived from rodents, SP34 or OKT-3 induce strong human anti-mouse antibody (HAMA) immunogenic responses in non-immunosuppressed humans, which limits their potential for administration and may also induce dangerous allergic reactions. In general, such immune responses require antigen presenting cells (APCs) to absorb therapeutic (foreign) proteins (i.e., therapeutic antibodies). Once entering such cells, proteins are processed, and the released fragments of proteins (some short peptide sequences form complexes with MHC class II molecules) are presented on the cell surface. If such complexes are identified by T cell receptor binding on T cells, such cells can be activated to produce stimulatory cytokines. Cytokines will cause B cells to differentiate into mature antibody-producing cells. In addition, such T cell responses may also produce other harmful effects on patients, such as inflammation and possible allergic reactions. However, it is understood that some peptides found to be combined with MHC class II molecules are recognized as "self" in the organism to which the final protein is applied, and therefore do not cause an immune response. For example, such peptides have been found in the variable region protein sequences of human germline immunoglobulins.

[0005] Therefore, humanized CD3-specific antibodies with reduced immunogenicity in humans are designed. A common aspect of the humanization process is to introduce a large amount of amino acid sequences with identity to the amino acid sequences present in human antibody proteins, so it is related to, for example, the CDR of non-human antibodies is transplanted into the closest human germline receptor antibody framework. A significant shortcoming associated with the humanization process is that the binding affinity of the resulting humanized antibodies is significantly reduced and the productivity and stability are poor. Restoring the original properties is usually achieved by the iterative process of returning human residues to the amino acid at the same position in non-human donor antibodies. However, this type of back mutation may increase the risk of inducing immunogenic reactions in humans again.

[0006] Therefore, the use of human antibodies seems to be an ideal solution to overcome the above-mentioned shortcomings of using murine or humanized antibodies, because the immune response generally does not affect autologous circulating proteins (such as immunoglobulins). However, when administered to certain individuals, human antibodies may still trigger an immune response or be immunogenic. For example, recombinant human antibodies selected from human phage display libraries may still use non-germline encoded protein sequences, such as consensus framework sequences from human framework sequence analysis, which may trigger an immune response. In addition, the variability introduced in the CDR region (especially during the affinity maturation process of the initially selected antibody) may cause an immune response. Such selected CDR amino acid sequences may be similar to foreign proteins and therefore can provide epitopes that are generally not used by the immune system.

[0007] As mentioned above, for CD3 targeted therapy, avoiding any unnecessary T cell activation is of utmost importance. An immune response against therapeutic CD3-specific antibodies can restore the unwanted cross-linking of bivalent or multivalent CD3 binding and CD3 complexes on T cells, thereby restoring their activation. Therefore, the present invention mainly adopts a new approach to provide optimized fully human antibodies specific for CD3, characterized in that potential T cell epitopes present in the CDR regions of their parent fully human antibody counterparts are removed, so once administered, the risk of eliciting an immune response in humans is reduced. Summary of the invention

[0008] The present disclosure provides affinity-optimized human CD3-specific antibodies and deimmunized variants thereof. The affinity-optimized antibodies are altered in their complementarity determining regions (CDRs) to reduce their immunogenicity in humans or reduce their risk of eliciting an immune response in humans after administration.

[0009] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising

[0010] i. The heavy chain variable region (VH), which comprises

[0011] (a) a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence GFSFGSHYMS (SEQ ID NO: 1),

[0012] (b) a HCDR2 comprising the amino acid sequence NINQIGYSSYYVESVKG (SEQ ID NO: 2), NINQIGYSSYYGESVKG (SEQ ID NO: 3) or NINQIGYSSYYEESVKG (SEQ ID NO: 4), and

[0013] (c) a HCDR3 comprising the amino acid sequence GYSAEFAHRSGLDV (SEQ ID NO: 5), GYSDEFATRSGLDV (SEQ ID NO: 6), GYSEEFAHRSGLDV (SEQ ID NO: 7), GYSDEFAKRSGLDV (SEQ ID NO: 8) or GYSDEFAHRSGLDV (SEQ ID NO: 9), and

[0014] ii. a variable light chain region (VL), which comprises

[0015] (a) a light chain complementary determining region (LCDR) 1 comprising the amino acid sequence SGSSSNIGSNYVY (SEQ ID NO: 10),

[0016] (b) LCDR2 comprising the amino acid sequence RNNQRPS (SEQ ID NO: 11), and

[0017] (c) LCDR3 comprising the amino acid sequence AGWSRSLHGAV (SEQ ID NO: 12) or AGWSRELHGAV (SEQ ID NO: 13).

[0018] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, wherein the antibody or antigen-binding fragment thereof cross-reactively binds to cynomolgus CD3.

[0019] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, wherein the antibody or antigen-binding fragment is a deimmunized antibody.

[0020] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, wherein the antibody or antigen-binding fragment thereof has a reduced risk of eliciting an immune response in a human.

[0021] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, wherein the antibody or antigen-binding fragment thereof comprises: a VH comprising an amino acid sequence having at least about 95%, 96%, 97%, 98%, 99% or 100% identity with an amino acid sequence selected from SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19, and / or a VL comprising an amino acid sequence having at least about 95%, 96%, 97%, 98%, 99% or 100% identity with an amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 21.

[0022] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, wherein VH and VL are selected from:

[0023] i. a VH comprising the amino acid sequence of SEQ ID NO: 14 and a VL comprising the amino acid sequence of SEQ ID NO: 20,

[0024] ii. a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0025] iii. a VH comprising the amino acid sequence of SEQ ID NO: 16 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0026] iv. a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0027] v. a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 21, and

[0028] vi. VH comprising the amino acid sequence of SEQ ID NO:19 and VL comprising the amino acid sequence of SEQ ID NO:21.

[0029] In one embodiment of the present disclosure, the isolated human antibody or antigen-binding fragment thereof specific for CD3 is a recombinant antibody or antigen-binding fragment thereof. In one embodiment of the present disclosure, the isolated human antibody or antigen-binding fragment thereof specific for CD3 is a monoclonal antibody or antigen-binding fragment thereof.

[0030] In one embodiment of the present disclosure, the isolated antigen-binding fragment specific for CD3 is Fab, Fab', (Fab')2, Fv or scFv. In one embodiment of the present disclosure, the isolated human antibody specific for CD3 is a full-length antibody.

[0031] In one embodiment, the present disclosure provides a bispecific antibody comprising a first antigen-binding fragment of a human antibody specific for CD3 separated according to the present disclosure and a second antigen-binding fragment of an antibody that binds to a target antigen different from the first antigen-binding fragment. In one embodiment of the present disclosure, the second antigen-binding fragment binds to a cell surface antigen, particularly to a tumor-associated cell surface antigen.

[0032] In one embodiment of the present disclosure, the isolated human antibody specific for CD3 according to the present disclosure or the bispecific antibody comprising an antigen-binding fragment of the isolated human antibody specific for CD3 according to the present disclosure comprises an Fc region, which comprises one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.

[0033] In one embodiment, the present disclosure provides a nucleic acid composition comprising a nucleic acid sequence or multiple nucleic acid sequences encoding an isolated human antibody specific for CD3 or an antigen-binding fragment thereof, or a bispecific antibody according to the present disclosure comprising an antigen-binding fragment of an isolated human antibody specific for CD3.

[0034] In one embodiment, the present disclosure provides a vector composition comprising: a vector or multiple vectors comprising a nucleic acid sequence or multiple nucleic acid sequences according to the present disclosure. In one embodiment, the present disclosure provides a host cell comprising a vector composition according to the present disclosure. In one aspect, the host cell is a mammalian cell. In one aspect, the host cell is a prokaryotic cell.

[0035] In one aspect, the present disclosure provides a method for producing an antibody or antigen-binding fragment thereof according to the present disclosure, comprising the steps of culturing the host cell under conditions suitable for antibody expression and optionally recovering the antibody or antigen-binding fragment thereof. In another aspect, the present disclosure provides an antibody or antigen-binding fragment thereof produced by the methods described herein.

[0036] In one embodiment, the present disclosure provides a pharmaceutical composition comprising: an isolated human antibody specific for CD3 or an antigen-binding fragment thereof according to the present disclosure, or a bispecific antibody comprising an antigen-binding fragment of an isolated human antibody specific for CD3 according to the present disclosure, and a pharmaceutically acceptable carrier or excipient.

[0037] In one embodiment, the present disclosure provides use of an isolated human antibody specific for CD3 or an antigen-binding fragment thereof or a pharmaceutical composition according to the present disclosure as a medicament.

[0038] The claimed antibodies or antigen-binding fragments thereof have utility. In addition, the claimed methods also have utility for producing such antibodies or antigen-binding fragments thereof. The claimed antibodies or antigen-binding fragments thereof are useful for targeting T cells expressing CD3 and stimulating T cell activation, for example, in situations where T cell-mediated killing is beneficial or desirable. In particular, the claimed antibodies or antigen-binding fragments thereof are useful for therapeutic purposes, such as treating cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 : Figure 1 A depicts the basic structure of the bispecific 2+1Fab2-Fc-scFv antibody format in Example 1. The bispecific antibody format comprises a glycosylated monoclonal IgG1 backbone plus an additional scFv antibody, wherein the N-terminus of the VL of the scFv is fused to the C-terminus of an IgG heavy chain via a peptide linker. In order to promote heterodimerization of two different heavy chains, knob-into-hole mutations were introduced into the two CH3-Fc domains. In addition to these mutations, the Fc region also includes amino acid substitutions, which result in the Fc region being unable to interact with IgG Fc receptors (Fcγ receptors) and complement. In this embodiment, both Fab arms of the bispecific antibody bind to HER2, while the scFv is specific for CD3. Figure 1 B depicts the basic structure of the bispecific 1+1Fab2-Fc antibody format of Example 2. This bispecific antibody format reflects the typical Y-shape of conventional IgG molecules, in which one Fab arm binds to the tumor target and the other Fab arm binds to CD3. The bispecific 1+1Fab2-Fc antibody is generated in vitro by Fab arm exchange. In order to be able to produce bispecific antibodies by this method, source IgG1 molecules carrying single mutations in the CH3 domain are generated: in one source IgG1 antibody, it is a F405L mutation (i.e., a CD3-specific antibody), and in another source IgG1 antibody, it is a K409R mutation (i.e., an anti-HER antibody). In addition to these mutations, the source IgG1 antibody also includes substitutions that result in the Fc region being unable to interact with the IgG Fc receptor (Fcγ receptor) and complement.

[0040] Figure 2: The basic structure of the bispecific Fab2-Fv-Fc antibody format of Example 3 and Example 4. The bispecific antibody format is constructed from a glycosylated monoclonal human IgG1 antibody backbone plus an additional Fv fragment, which is integrated between the Fc region and the two Fab arms of the IgG1 backbone. In this example, both Fab arms bind to HER2, while the "additional" Fv fragment contains the variable region of an antibody specific for CD3 according to the present disclosure. Figure 2 Also depicted are different improved peptide linkers for attaching additional Fv fragments to the Fab arms and Fc region.

[0041] Figure 3 : Cell binding of bispecific antibodies specific for HER2 and CD3 produced by mammals according to Example 2.2 (comprising variable domains of CD3-specific antibodies of affinity maturation or cross-cloning according to the present disclosure). Shown is the cell binding (signal above background) as a function of bispecific antibody concentration as determined by flow cytometry with CD3-positive Jurkat cells.

[0042] Figure 4 : In the presence of human T cells from a donor, the bispecific antibody specific for HER2 and CD3 produced by the mammal according to Example 2.4 (comprising the variable domains of the affinity matured or cross-cloned CD3-specific antibody disclosed herein) is activated against SKBR3 cells expressing HER2 ( Figure 4 A) or HER2-positive MCF-7 cells ( Figure 4 B) Cytotoxicity assay. The cytotoxic activity of human T cells was assessed by measuring the fluorescence of incorporated CellToxGreen. The figure shows the relative fluorescence levels of SKBR3 or MCF-7 cells expressing HER2 as a function of bispecific antibody concentration.

[0043] Figure 5 : T cell activation assay of bispecific antibodies specific for HER2 and CD3 produced by mammals according to Example 2.5 (comprising variable domains of CD3-specific antibodies affinity matured or cross-cloned according to the present disclosure). T cell activation was determined by evaluating CD69 expression on CD8-positive T cells assessed by flow cytometry. Shown is the percentage of CD69+ activated CD8+ T cells from 3 different donors as a function of bispecific antibody concentration.

[0044] Figure 6: Cytotoxicity assay of a bispecific antibody specific for HER2 and CD3 produced by a mammal according to Example 3.6, comprising the variable domains of a cross-cloned CD3-specific antibody (CD3-MABopt-cc) of Example 2 and the two most potent linker combinations (Linker Combination 2 and Linker Combination 5) (reference to the originally disclosed Linker Combination P). Killing of HER2-expressing SKBR3 cells in the presence of human T cells from one donor is shown. The cytotoxic activity of human T cells was assessed by measuring the fluorescence of incorporated CellToxGreen. The figure shows the relative fluorescence levels of HER2-expressing SKOV-3 cells as a function of bispecific antibody concentration.

[0045] Figure 7 : T cell activation assay of bispecific antibodies specific for HER2 and CD3 produced by mammals according to Example 3.7, the above-mentioned antibodies comprise the variable domains of a cross-cloned CD3-specific antibody (CD3-MABopt-cc) of Example 2 and 6 linker combinations (linker combinations 1-6) (refer to the originally disclosed linker combination P). By evaluating CD4+ T cells ( Figure 7 A) or CD8+ T cells ( Figure 7 B) T cell activation was determined by CD69 expression on the mitochondria, which was assessed by flow cytometry. Figure 7 A is a graph showing the average percentage of CD69+ activated CD4+ T cells from 3 different donors as a function of bispecific antibody concentration. Figure 7 B is a graph showing the average percentage of CD69+ activated CD8+ T cells from 3 different donors as a function of bispecific antibody concentration.

[0046] Figure 8 Epibase analysis of the HCDR3 region of the cross-cloned antibody CD3-MABopt-cc in Example 2 for identifying potential T cell epitopes TM (Lonza, Epibase version: v3.0) Computer screening results. Human antibody germline coding sequence regions were excluded from the analysis. For analysis, the entire VH sequence was split into overlapping 10-mer peptides, each peptide shifted by one amino acid. Figure 8 The left panel of FIG lists the 10-mer peptides analyzed, starting from amino acid position 90 to position 112 on the VH of CD3-MABopt-cc, spanning its entire HCDR3 region. Figure 8As shown in the upper figure / column, the potential peptide / HLA binding of each analyzed 10-mer peptide was determined for the HLA class II isotypes of the major Caucasian DRB1 alleles. For each DRB1 isotype, its natural occurrence frequency is provided (e.g., DRB1*01:01: 15%). For example, peptide 93 is expected to bind to 3 isotypes of the DRB1 allele with a medium affinity (M) and to 2 isotypes of the DRB1 allele with a strong affinity (S). Such peptides reflect the "T cell epitope" defined herein. The risk score provided for this peptide is 24.5, calculated as the sum of the natural occurrence frequencies of the isotypes of the DRB1 alleles to which such peptides bind (e.g., peptide 93: 24+6+12+6+5=53 (approximately), exact value: 51.9). In summary, 10 T-cell epitopes (peptides 92, 93, 94, 95, 97, 100, 102, 104, 110, 112) and 2 hotspots could be assigned to the HCDR3 region of CD3-MABopt-cc (the first hotspot spans peptides 92–97 and the second hotspot spans peptides 110–112). Hotspots reflect the accumulation of neighboring T-cell epitopes. Such hotspots were identified based on “4 over 3”, meaning that at least 4 isoforms of the DRB1 allele must bind with moderate or strong affinity to at least two of the three consecutively analyzed 10-mer peptides. In addition, at most one 10-mer peptide that was not identified as a T-cell epitope could be part of a hotspot. Therefore, not every identified T-cell epitope has to be part of a hotspot (see e.g. Figure 8 On the other hand, peptides that have not been identified as T cell epitopes may still be part of a hotspot (see, e.g. Figure 4 Each 10-mer peptide analyzed as part of a hotspot is defined as an H-line. The cumulative risk score of a hotspot can be calculated as the sum of the risk scores determined for each T cell epitope within the hotspot, which is defined herein as the "H-score". For example, the second hotspot of HCDR3 consists of 3 H-lines. Therefore, the H-score is calculated as the sum of the risk scores of each T cell epitope covered by this hotspot, for example 27.8+60.3=88.

[0047] Fig. 9 : Epibase TM In silico mutation analysis: CD3-mAb opt-cc In silico single amino acid substitutions at each HCDR3 position (positions 92–112) (top panel) for CD3-mAb opt-cc The number of T cell epitopes of VH ( Figure 4 Left panel) and the corresponding absolute risk score ( Figure 4 Numbers with bold borders indicate the effects of CD3-mAb opt-ccThe amino acid substitutions for gene synthesis of each VH variant of the invention are preferably selected to reduce the number of T cell epitopes by 2 or more and to allow conservative amino acid substitutions. In addition, care is taken not to introduce potential post-translational modification sites ("PTM motifs") into the CDR region. For example, for HCDR3, 42 single amino acid substitutions (single-point variants) were selected for gene synthesis.

[0048] Fig.10 : After characterization in the bispecific Fab2-Fv-Fc antibody format of Example 4, CD3-MAB opt-cc Summary of biophysical and functional properties of 27 preferred CDR single-point variants. For each substitution, the CD3-mAb opt-cc The reduction of T cell epitopes in the VH or VL of the purified bispecific antibody preparations, as well as the monomer content and yield, ELISA binding and affinity to recombinant human CD3ε. Fig.10 The last column depicts the variants selected for the combined in silico mutation analysis. The first row (wt (parental)) represents the variants selected for the CD3-mAb containing antibody opt-cc Functional properties of the variable domains of bispecific antibodies were determined.

[0049] Fig.11 : Epibase TM In silico combined mutation analysis of CD3-mAb opt-cc Example results of 54 combined amino acid substitutions in the HCDR1-3 region of CD3-MAB, resulting in the reduction of 3 hot spots. The first row of the table shown represents the CD3-MAB opt-cc Risk parameters (absolute score, hotspots, absolute H-score and absolute H-line) of VH of . For each combination variant, each risk parameter relative to CD3-MAB is provided. opt-cc The reduction in risk parameters determined by the VH of

[0050] Fig.12 : After characterization in the bispecific Fab2-Fv-Fc antibody format of Example 4, 33 preferred CD3-MAB opt-cc Summary of the biophysical and functional properties of the combinatorial variants. The first row represents the variants targeting CD3-mAb opt-cc For each combination variant, each risk parameter (absolute score, hotspot, absolute H value and absolute H-line) is provided relative to the CD3-MAB opt-ccIn addition, the monomer content, ELISA binding and affinity to recombinant human CD3ε antigen of the purified bispecific antibody preparations and the functional activity in the receptor gene assay on SKOV-3 cells at two bispecific antibody concentrations are shown.

[0051] Fig.13 : Cytotoxicity assay of the mammalian produced bispecific antibody BissIg_21_CD3-MABdeimm_3 comprising the VH and VL sequences of the most preferred deimmunized combinatorial variant CD3-MABdeimm_3 (reference bispecific antibody BissIg_21_CD3-MABopt_cc comprising the unchanged variable domains of the CD3-specific CD3-MABopt_cc) performed on one donor according to Example 4.12. The cytotoxic activity of human T cells was assessed by measuring the fluorescence of the incorporated CellToxGreen. The figure shows the relative fluorescence levels of HER2-expressing SKOV-3 cells as a function of the bispecific antibody concentration.

[0052] Fig.14 : An exemplary T cell activation assay for the bispecific antibodies BissIg_21_CD3-MABdeimm_1, BissIg_21_CD3-MABdeimm_2, BissIg_21_CD3-MABdeimm_3, BissIg_21_CD3-MABdeimm_4, BissIg_21_CD3-MABdeimm_5 comprising the 5 most preferred deimmunized combinatorial variant VH and VL sequences (with reference to the bispecific antibody BissIg_21_CD3-MABopt_cc comprising the unchanged variable domains of the CD3-specific CD3-MABopt_cc) was determined according to Example 4.13. As a positive control, the results of murine CD3-specific OKT-3 IgG are shown. The activation of T cells was assessed by flow cytometry for CD4+ T cells ( Fig.14 A) and CD8+ T cells ( Fig.14 B) was measured by CD69 expression on the 1000 T cells. The figure shows the average percentage of CD69+ activated CD4+ T cells or CD8+ T cells from one donor, respectively, as a function of the bispecific antibody concentration. DETAILED DESCRIPTION

[0053] definition

[0054] "CD3" refers to an antigen expressed on T cells as part of a multimolecular T cell receptor (TCR) composed of a homodimer or heterodimer formed by the association of two of four receptor chains: CD3ε (CD3 epsilon), CD3δ, CD3ζ, and CD3γ.

[0055] Human CD3ε (or human CD3e) has the amino acid sequence of UniProt P07766:

[0056]

[0057] (Signal sequence underlined, intracellular region italicized, transmembrane region bold).

[0058] The mature extracellular domain of human CD3ε without the signal sequence comprises amino acid residues 22-126, and its amino acid sequence is:

[0059]

[0060] Cynomolgus monkey CD3ε (or cyno CD3e) has the amino acid sequence of UniProt Q95LI5

[0061]

[0062] (Signal sequence underlined, intracellular region italicized, transmembrane region bold).

[0063] The mature extracellular region of cynomolgus monkey CD3ε without the signal sequence comprises amino acid residues 22-198, and its amino acid sequence is:

[0064]

[0065] When used to refer to a specific numerical value, the term "about" means that the value may differ from the stated value by no more than 1%. For example, the expression "about 100" used herein includes 99 and 101 and all values ​​therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0066] As used herein, the term "antigen" or "target antigen" refers to any target molecule that can be bound by one of the binding sites present in an antibody. Typically, an antigen is a peptide, protein, or any other protein molecule. Alternatively, an antigen can be any other organic or inorganic molecule, such as a carbohydrate, fatty acid, lipid, dye, or fluorophore.

[0067] The term "antibody" as used herein refers to a protein comprising at least two heavy chains (H) and two light chains (L) interconnected by disulfide bonds, which interact with an antigen. Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region consists of three domains CH1, CH2 and CH3. Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region consists of one domain CL. The VH and VL regions can be further subdivided into hypervariable regions, called complementary determining regions (CDRs), interspersed with more conservative regions, called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of an antibody can mediate the binding of an immunoglobulin to a host tissue or factor, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. The term "antibody" includes, for example, monoclonal antibodies, human antibodies, humanized antibodies, camel antibodies, and chimeric antibodies. The antibody can be of any isotype (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass. The light chain and heavy chain are divided into structural and functional homology regions. The structure and position of immunoglobulin variable domains (e.g., CDRs) can be defined using well-known numbering schemes, such as the Kabat numbering scheme, the Chothia numbering scheme, or a combination of Kabat and Chothia (see, e.g., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services (1991), Kabat et al., eds.; Lazikani et al., (1997) J. Mol. Biol. 273:927-948); Kabat et al., (1991) Sequences of Proteins of Immunological Interest, 5th ed., NIH Publication no. 91-3242 U.S. Department of Health and Human Services; Chothia et al., (1987) J. Mol. Biol. 196:901-917; Chothia et al., (1989) Nature 500:1131-114; 342:877-883; and Al-Lazikani et al., (1997) J. Mol. Biol. 273:927-948). As used herein, the term "antibody" is intended to include monospecific antibodies as well as bispecific and multispecific antibodies.

[0068] As used herein, the term "antibody fragment" or "antigen-binding fragment" of an antibody refers to one or more portions of an antibody that retain the ability to specifically interact with an antigen (e.g., by binding, steric hindrance, stabilizing spatial distribution). Examples of antibody fragments or antigen-binding fragments include, but are not limited to, a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; a F(ab)2 fragment, a bivalent fragment consisting of two Fab fragments linked by a disulfide bond at the hinge region; a Fd fragment consisting of the VH and CH1 domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a dAb fragment consisting of the VH domain (Ward et al., (1989) Nature 341: 544-546); and isolated complementarity determining regions (CDRs). In addition, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be connected by synthetic linkers using recombinant methods to make them into a single protein chain in which the VL and VH domains pair to form a monovalent molecule (called single-chain Fv (scFv); see, e.g., Bird et al., (1988) Science 242:423-426; and Huston et al., (1988) Proc. Natl. Acad. Sci. 85:5879-5883). Such single-chain antibodies are also intended to be included in the term "antibody fragment" or "antigen-binding fragment". These antibody fragments are obtained using conventional techniques known to those skilled in the art, and the utility of the fragments is screened in the same manner as intact antibodies. Antibody fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs and bi-scFvs (see, e.g., Hollinger and Hudson, (2005) Nature Biotechnology 23: 1126-1136). Antibody fragments can be implanted into scaffolds based on polypeptides such as fibronectin type III (Fn3) (see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide monomers). Antibody fragments or antigen binding fragments can be incorporated into single chain molecules comprising a pair of tandem Fv fragments (VH-CH1-VH-CH1), which together with complementary light chain polypeptides form a pair of antigen binding sites (Zapata et al., (1995) Protein Eng. 8: 1057-1062; and U.S. Pat. No. 5,641,870).

[0069] The term "Fc region" as used herein refers to two Fc region subunits that can stably bind to each other to form a dimeric C-terminal region of an immunoglobulin. Therefore, the two Fc region subunits (e.g., the first Fc region subunit and the second Fc region subunit) are complementary to each other. The Fc region of a conventional IgG molecule exists in a dimer form, each of which subunits comprises a CH2 and CH3 IgG heavy chain constant domain.

[0070] As used herein, "Fc region subunit" refers to one of the two polypeptides forming the dimeric Fc region of an immunoglobulin, i.e., a polypeptide comprising the C-terminal constant region of an immunoglobulin heavy chain, which can stably self-bind. Therefore, the two Fc region subunits (e.g., the first and second Fc region subunits) forming the dimeric Fc region are complementary to each other. For example, the IgG Fc region subunit comprises IgG CH2 and IgG CH3 constant domains. The term includes native sequence Fc region subunits and variant Fc region subunits. Although the boundaries of the Fc region subunits of the IgG heavy chain may be slightly different, the human IgG heavy chain Fc region subunit is generally defined as extending from Cys226 or from Pro230 to the C-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region subunit may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region is according to the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, Public Health Service, National Institutes of Health, Bethesda, Maryland, 1991.

[0071] As used herein, "human antibodies" or "human antibody fragments" or "human antigen-binding fragments" include antibodies and antibody fragments having variable regions, wherein both the framework region and the CDR region are derived from human sequences. In addition, if the antibody contains a constant region, the constant region is also derived from such sequences. Human sources include, for example, human germline sequences, or mutant versions of human germline sequences, or antibodies containing consensus framework sequences derived from human framework sequence analysis, for example, as described in Knappik et al., (2000) J Mol Biol 296:57-86. Therefore, the human antibodies can be obtained from a technology platform that includes antibodies derived from human germline genes, which are generated or synthetically generated from VHA / L libraries isolated from B cells by PCR amplification. Technology platforms include library-based methods, including human immunoglobulin genes displayed on phage, ribosomes or yeast. The respective display technologies are standard in the scientific community. In addition, immunization of transgenic mice carrying human immunoglobulin libraries is another method for generating human antibodies against the target antigen. From a MorphoSys-based Concept (Knappik et al., (2000) J Mol Biol 296:57-86) or Antibodies or fragments thereof selected from the antibody library of the concept library (Tiller et al. mAbs 5:3, 1–26; May / June (2013) and US Pat. No. 8,728,981) are considered to be fully human antibodies.

[0072] The term "isolated" refers to a compound, which may be, for example, an antibody or antibody fragment or antigen-binding fragment, which is substantially free of other antibodies or antibody fragments having different antigenic specificities. Thus, in certain aspects, the antibodies provided are isolated antibodies that have been separated from antibodies having different specificities. The isolated antibodies may be monoclonal antibodies. The isolated antibodies may be recombinant monoclonal antibodies. However, isolated antibodies that specifically bind to an epitope, isomer or variant of a target may have cross-reactivity with other related antigens, such as from other species (e.g., species homologs).

[0073] The term "recombinant antibody" as used herein includes all antibodies or antigen-binding fragments prepared, expressed, produced or separated by a method not present in nature. For example, antibodies isolated from host cells transformed to express antibodies, antibodies selected and separated from recombinant, combined human antibody libraries, and antibodies prepared, expressed, produced or separated by any other method, the method involving splicing all or part of the sequence of human immunoglobulin genes into other DNA sequences, or antibodies isolated from transgenic or transchromosomal human immunoglobulin gene animals (such as mice) or hybridomas prepared therefrom. Preferably, such recombinant antibodies have variable regions, wherein the framework and CDR regions are derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies can be subjected to in vitro mutagenesis (or, when using animals of transgenic human Ig sequences, in vivo somatic mutagenesis is performed), so the amino acid sequences of the VH and VL regions of the recombinant antibodies are such sequences, although they are derived from and related to human germline VH and VL sequences, they may not naturally exist in the human antibody germline library in vivo. The recombinant antibody can be a monoclonal antibody.

[0074] As used herein, the term "monoclonal antibody" refers to an antibody derived from a single clone, including any eukaryotic, prokaryotic or phage clone, rather than the method of its production. The monoclonal antibodies disclosed herein can be prepared by the hybridoma method described in Kohler et al.; Nature, 256:495 (1975), or can be isolated from a phage library using the techniques described herein. Other methods for preparing clonal cell lines and monoclonal antibodies expressed therein are well known in the art (see, e.g., Short Protocols in Molecular Biology, (2002) 5th edition, Chapter 11, edited by Ausubel et al., John Wiley and Sons, New York). Other exemplary methods for producing other monoclonal antibodies are provided in the Examples herein.

[0075] As used herein, an antibody "specifically binds", "specifically binds", "specifically targets" or "specifically recognizes" an antigen if it is able to distinguish between such an antigen and one or more reference antigens, since binding specificity is not absolute but relative. For example, a standard ELISA assay can be performed. Scoring can be performed by standard color development (e.g., secondary antibody with horseradish peroxide and tetramethylbenzidine with hydrogen peroxide). The reaction in certain wells is scored by optical density, for example at 450nm. A typical background (= negative reaction) may be 0.1OD; a typical positive reaction may be 1OD. This means that the positive / negative difference may be more than 10 times. Typically, the determination of binding specificity is not performed by using a single reference antigen, but by using a group of about three to five unrelated antigens (e.g., milk powder, BSA, transferrin, etc.).

[0076] As used herein, "antibodies or antigen-binding fragments thereof that bind to CD3" or "anti-CD3 antibodies or antigen-binding fragments thereof" or "antibodies or antigen-binding fragments thereof specific for CD3" include antibodies and antibody fragments thereof or antigen-binding fragments thereof that specifically recognize one or more CD3 subunits (e.g., ε), as well as antibodies and antibody fragments thereof that specifically recognize a dimeric complex of two CD3 subunits (e.g., γ / ε, δ / ε). The antibodies and antigen-binding fragments thereof disclosed herein can bind to soluble CD3 and / or CD3 expressed on the cell surface. Soluble CD3 includes natural CD3 proteins as well as recombinant CD3 protein variants, for example, monomeric and dimeric CD3 constructs that lack a transmembrane domain or are not associated with a cell membrane.

[0077] As used herein, the term "cell surface" refers to one or more proteins expressed on the surface of a cell in vitro or in vivo, so that at least a portion of the protein is exposed to the extracellular side of the cell membrane and can be contacted by the antigen-binding portion or fragment of an antibody."CD3 expressed on the cell surface" includes CD3 proteins contained in functional T cell receptors in the cell membrane. The statement "CD3 expressed on the cell surface" includes CD3 proteins (e.g., γ / ε, δ / ε and ζ / ζCD3 dimers) expressed on the cell surface as a part of a homodimer or heterodimer. The statement "CD3 expressed on the cell surface" also includes CD3 chains (e.g., CD3ε) expressed alone on the cell surface without other CD3 chain types. "CD3 expressed on the cell surface" may include CD3 proteins expressed on the surface of cells that usually express CD3 proteins, or be composed of them. Alternatively, "CD3 expressed on the cell surface" may include CD3 proteins expressed on the cell surface, or be composed of them, and the cell does not usually express human CD3 on its surface, but has been artificially modified to express CD3 on its surface.

[0078] The term "cross-reactive binding" or the term "having cross-reactivity" are used interchangeably herein and refer to antibodies or antigen-binding fragments that have the ability to specifically bind to multiple antigens. For example, an antibody according to the present disclosure cross-reactively binds to cynomolgus CD3 (e.g., cynomolgus CD3ε).

[0079] As used herein, the term "affinity" refers to the strength of interaction between an antibody and its target at a single site. Within each site, the binding domain of an antibody interacts with its target at multiple sites through weak non-covalent forces; the more interactions, the stronger the affinity.

[0080] The term "K D ” refers to the dissociation constant, which is given by K d With K a The ratio (i.e. K d / K a ) and expressed as a molar concentration (M). The K of an antigen-binding moiety (e.g., a monoclonal antibody) D The K value can be determined using methods established in the art. Determination of the K of an antigen binding portion (e.g., a monoclonal antibody) D The methods are SET (soluble equilibrium titration) or the use of biosensor systems (e.g. In the present disclosure, antibodies specific for CD3ε polypeptides generally have a surface plasmon resonance of less than 5×10 -2 M, less than 10 -2 M, less than 5x10 -3 M, less than 10 -3 M, less than 5x10 -4 M, less than 10-4 M, less than 5x10 -5 M, less than 10 -5 M, less than 5x10 -6 M, less than 10 -6 M, less than 5x10 -7 M, less than 10 -7 M, less than 5x10 -8 M, less than 10 -8 M, less than 5x10 -9 M, less than 10 -9 M, less than 5x10 -10 M, less than 10 -10 M, less than 5x10 -11 M, less than 10 -11 M, less than 5x10 -12 M, less than 10 -12 M, less than 5x10 -13 M, less than 10 -13 M, less than 5x10 -14 M, less than 10 -14 M, less than 5x10 -15 M, or less than 10 -15 The dissociation rate constant (K D )(k off / k on ).

[0081] The compositions of the present disclosure can be used for therapeutic or preventive applications. Therefore, the present disclosure includes pharmaceutical compositions containing antibodies (or antigen-binding fragments thereof) disclosed herein and pharmaceutically acceptable carriers or excipients. In related aspects, the present disclosure provides a method for treating cancer. The method comprises the step of administering an effective amount of a pharmaceutical composition containing an antibody (or antigen-binding fragment thereof) described herein to a subject in need thereof. The present disclosure provides a method of treatment, comprising administering a therapeutically effective amount of a human antibody or antigen-binding fragment thereof disclosed herein that is specific for CD3 to a subject in need of such treatment. "Therapeutically effective amount" or "effective amount" as used herein refers to the amount of CD3-specific antibodies required to elicit a desired biological response. According to the present disclosure, a therapeutically effective amount is the amount of CD3-specific antibodies or antigen-binding fragments thereof required to treat and / or prevent a disease.

[0082] The terms "cell proliferative disease" or "proliferative disease" refer to diseases that are associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disease is cancer. In one embodiment, the cell proliferative disease is a tumor. The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.

[0083] The term "tumor-associated antigen" refers to an antigen expressed or present on the surface of tumor or tumor stromal cells.

[0084] "Increase" refers to the ability to cause an overall increase, for example, 20% or more, 50% or more, or 75%, 85%, 90%, 95% or more.

[0085] As used herein, the term "EC50" refers to the concentration of an antibody or antibody fragment or bispecific antibody that induces a response halfway between baseline and maximum in an assay. It represents the antibody concentration at which 50% of the maximal effect is observed.

[0086] As used herein, the term "IC50" refers to the concentration of an antibody or antibody fragment or bispecific antibody that inhibits the response halfway between the maximum response and the baseline in an assay. It represents the antibody concentration that reduces a given response by 50%.

[0087] The term "inhibition" or "inhibit" or "reduction" or "neutralization" or "neutralize" or the like refers to a reduction or cessation of any phenotypic characteristic (e.g., binding, biological activity, or function), or a reduction or cessation of the incidence, degree, or likelihood of the characteristic. "Inhibition," "reduction," or "neutralization," etc. do not need to be complete, as long as they can be detected using appropriate assays. In certain aspects, "reduction" or "inhibition," etc. refers to being able to cause a 20% or more reduction. In another aspect, "reduction" or "inhibition" refers to being able to cause a 50% or more reduction. In another aspect, "reduction" or "inhibition," etc. refers to being able to cause an overall reduction of 75%, 85%, 90%, 95% or more.

[0088] "Administration" or "application" includes but is not limited to delivering the drug by an injectable form, such as intravenous, intramuscular, intradermal or subcutaneous route or mucosal route, such as as a nasal spray or inhalation aerosol or as an ingestible solution, capsule or tablet. Preferably, administration is in the form of injection.

[0089] As used herein, "treatment", "treat" or "treating" refers to a clinical intervention that attempts to change the natural course of a disease in a subject to be treated, and can be used for prevention or performed during clinical pathology. The desired effects of treatment include, but are not limited to, preventing the occurrence or recurrence of a disease, alleviating symptoms, alleviating any direct or indirect pathological consequences of a disease, preventing metastasis, reducing the rate of disease progression, improving or alleviating the disease state, and alleviating or improving prognosis. In certain aspects, antibodies or antigen-binding fragments thereof according to the present disclosure are used to delay the development of a disease or slow the progression of a disease.

[0090] The term "multispecific" refers to the ability of an antibody to specifically bind to two or more different antigens. Typically, a multispecific antibody consists of two or more antigen binding sites, each specific for a different antigen or epitope.

[0091] The term "bispecific" refers to the ability of an antibody to specifically bind to two different antigens. Typically, a bispecific antibody contains two antigen-binding sites, each specific for a different antigen or epitope.

[0092] As used herein, the terms "first" and "second" and the like are used to distinguish components of each type or when there is more than one of a type. Unless explicitly stated, the use of these terms is not intended to confer a particular order or direction.

[0093] As used herein, "amino acid residue" or "amino acid" will be referred to by its full name or according to the standard three-letter or one-letter amino acid code. "Naturally occurring amino acid" refers to the following amino acids:

[0094] Table 1: Naturally occurring amino acids

[0095]

[0096]

[0097] "Effector functions" refer to those biological activities attributed to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors); and B cell activation.

[0098] As used herein, "species" refers to any mammal, including rodents, such as mice or rats, and primates, such as cynomolgus monkeys (Macaca fascicularis), rhesus monkeys (Macaca mulatta) or humans (Homosapiens). Preferably, the subject is a primate, most preferably a human.

[0099] "Deimmunization" refers to a method in which amino acids in a given antibody sequence predicted to effectively bind to HLA molecules are changed so that they no longer bind to HLA and are therefore no longer able to stimulate a T cell response. Thus, deimmunization renders a given protein or polypeptide non-immunogenic or less immunogenic to a given species. Elimination of T cell epitopes from proteins has been previously disclosed (see WO 98 / 52976). A suitable technique for deimmunizing antibodies is described, for example, in WO 00 / 34317 or WO2003 / 105058. For therapeutic antibodies, it is preferred to remove all potential T cell epitopes while retaining the functional activity of the unmodified parent antibody.

[0100] As used herein, a "deimmunized" antibody refers to an antibody that has been deimmunized. A "deimmunized" antibody may be less immunogenic or non-immunogenic in a given species compared to the unmodified parent antibody when used in vivo.

[0101] The term "T cell epitope" or "potential T cell epitope" or "MHC class II binding motif" as used herein refers to a specific 10-mer peptide sequence within a given protein or polypeptide sequence that can bind to MHC class II molecules with reasonable efficiency, or bind strongly to the T cell receptor of a species in the form of a peptide:MHC complex to receive therapeutic proteins, or show the ability to stimulate T cells through presentation on MHC class II. Potential T cell epitopes can be measured by any computational or physical method to establish MHC binding.

[0102] The term "hotspot" as used herein refers to a region within a given antibody heavy or light chain variable region with accumulation of adjacent (predicted) T cell epitopes. Hotspots according to the present disclosure are identified by the 4over3 algorithm detailed in Figure 8 and Example 4.1, and require that at least 4 isoforms of the DRB1 allele bind to at least two of three consecutively analyzed 10-mer peptides with medium (M) or strong (S) affinity. In addition, at most one 10-mer peptide that has not been identified as a T cell epitope can be part of a hotspot.

[0103] The term "risk score" as used herein provides a numerical value as a measure of the risk that a T cell epitope (10-mer peptide analyzed) will cause an immune reaction or immune response in a specific population (e.g., a Caucasian population). The larger the value, the higher the risk. The risk score of a T cell epitope is calculated as the sum of the naturally occurring population frequencies of the DRB1 alleles (HLA allotypes) to which such T cell epitopes (10-mer peptides) bind. The risk score is determined by the calculation method described in Example 4 herein, using a commercially available computer screening tool: Epibase TM , Epibase version: v3.0 (Lonza). The basic method is described in WO 2003 / 105058.

[0104] As used herein, the term "absolute risk score" or "score" provides a numerical value as a measure of the risk of the entire analyzed polypeptide to elicit an immune reaction or immune response in a given population (e.g., a Caucasian population). The "absolute risk score" is calculated as the sum of all individual risk scores determined for all T cell epitopes present in the analyzed polypeptide sequence (e.g., the entire VH or VL sequence of an antibody).

[0105] As used herein, "H-line" refers to an analyzed 10-mer peptide sequence of an antibody heavy or light chain variable region identified as part of a hotspot.

[0106] As used herein, the "H-line" provides a numerical value for the sum of analyzed 10-mer peptide sequences of the antibody heavy or light chain variable region identified as part of a hotspot.

[0107] As used herein, "absolute H-line" provides a value for the sum of the H-lines that are a portion of all identified hot spots in a polypeptide.

[0108] As used herein, an "H-score" provides a numerical value that measures the risk of a hotspot causing an immune response or immune reaction in a given population (e.g., a Caucasian population). The H-score is calculated as the sum of the individual risk scores determined for all T cell epitopes of the hotspot.

[0109] As used herein, "absolute H-score" provides a numerical value as a measure of the cumulative risk of all hot spots identified in a given antibody heavy chain or light chain variable region to cause an immune reaction or immune response in a given population (e.g., a Caucasian population). The absolute H-score is calculated as the sum of the risk scores determined for all T cell epitopes for all identified hot spots in a given antibody heavy chain or light chain variable region.

[0110] Embodiments of the present disclosure

[0111] According to the present disclosure, affinity-optimized human antibodies specific for CD3 are listed in Tables 5 and 6. According to the present disclosure, deimmunized human antibodies specific for CD3 are listed in Table 7. In one aspect, the present disclosure relates to an isolated human antibody specific for CD3 or an antigen-binding fragment thereof, which comprises the 6 CDRs of any one of the antibodies listed in Tables 5-7. In one aspect, the present disclosure relates to an isolated human antibody or an antigen-binding fragment thereof, which comprises the VH and VL of any one of the antibodies listed in Tables 5-7.

[0112] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), the antibody or antigen-binding fragment thereof comprising

[0113] i. The heavy chain variable region (VH), which comprises

[0114] (a) a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence GFSFGSHYMS (SEQ ID NO: 1),

[0115] (b) a HCDR2 comprising the amino acid sequence NINQIGYSSYYVESVKG (SEQ ID NO: 2), NINQIGYSSYYGESVKG (SEQ ID NO: 3) or NINQIGYSSYYEESVKG (SEQ ID NO: 4), and

[0116] (c) a HCDR3 comprising the amino acid sequence GYSAEFAHRSGLDV (SEQ ID NO: 5), GYSDEFATRSGLDV (SEQ ID NO: 6), GYSEEFAHRSGLDV (SEQ ID NO: 7), GYSDEFAKRSGLDV (SEQ ID NO: 8) or GYSDEFAHRSGLDV (SEQ ID NO: 9), and

[0117] ii. a variable light chain region (VL), which comprises

[0118] (d) a light chain complementary determining region (LCDR) 1 comprising the amino acid sequence SGSSSNIGSNYVY (SEQ ID NO: 10),

[0119] (e) LCDR2 comprising the amino acid sequence RNNQRPS (SEQ ID NO: 11), and

[0120] (f) LCDR3 comprising the amino acid sequence AGWSRSLHGAV (SEQ ID NO: 12) or AGWSRELHGAV (SEQ ID NO: 13).

[0121] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, comprising a VH and a VL, wherein the VH comprises:

[0122] a) a HCDR1 region comprising the amino acid sequence of SEQ ID NO: 22,

[0123] b) a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 23, and

[0124] c) a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 5,

[0125] The VL comprises:

[0126] d) a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 10,

[0127] e) a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 11, and

[0128] f) a LCDR3 region comprising the amino acid sequence of SEQ ID NO:12.

[0129] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, comprising a VH and a VL, wherein the VH comprises:

[0130] a) a HCDR1 region comprising the amino acid sequence SEQ ID NO: 1,

[0131] b) a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 2, and

[0132] c) a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 5,

[0133] The VL comprises:

[0134] d) a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 10,

[0135] e) a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 11, and

[0136] f) a LCDR3 region comprising the amino acid sequence of SEQ ID NO:24.

[0137] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, comprising a VH and a VL, wherein the VH comprises:

[0138] a) a HCDR1 region comprising the amino acid sequence SEQ ID NO: 1,

[0139] b) a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 2, and

[0140] c) a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 5,

[0141] The VL comprises:

[0142] d) a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 10,

[0143] e) a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 11, and

[0144] f) a LCDR3 region comprising the amino acid sequence of SEQ ID NO:12.

[0145] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, comprising a VH and a VL, wherein the VH comprises:

[0146] a) a HCDR1 region comprising the amino acid sequence SEQ ID NO: 1,

[0147] b) a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 4, and

[0148] c) a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 7,

[0149] The VL comprises:

[0150] d) a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 10,

[0151] e) a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 11, and

[0152] f) a LCDR3 region comprising the amino acid sequence of SEQ ID NO:13.

[0153] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, comprising a VH and a VL, wherein the VH comprises:

[0154] a) a HCDR1 region comprising the amino acid sequence SEQ ID NO: 1,

[0155] b) a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 3, and

[0156] c) a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 9,

[0157] The VL comprises:

[0158] d) a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 10,

[0159] e) a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 11, and

[0160] f) a LCDR3 region comprising the amino acid sequence of SEQ ID NO:13.

[0161] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, comprising a VH and a VL, wherein the VH comprises:

[0162] a) a HCDR1 region comprising the amino acid sequence SEQ ID NO: 1,

[0163] b) a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 3, and

[0164] c) a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 6,

[0165] The VL comprises:

[0166] d) a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 10,

[0167] e) a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 11, and

[0168] f) a LCDR3 region comprising the amino acid sequence of SEQ ID NO:13.

[0169] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, comprising a VH and a VL, wherein the VH comprises:

[0170] a) a HCDR1 region comprising the amino acid sequence SEQ ID NO: 1,

[0171] b) a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 3, and

[0172] c) a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 7,

[0173] The VL comprises:

[0174] d) a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 10,

[0175] e) a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 11, and

[0176] f) a LCDR3 region comprising the amino acid sequence of SEQ ID NO:13.

[0177] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, comprising a VH and a VL, wherein the VH comprises:

[0178] a) a HCDR1 region comprising the amino acid sequence SEQ ID NO: 1,

[0179] b) a HCDR2 region comprising the amino acid sequence of SEQ ID NO: 3, and

[0180] c) a HCDR3 region comprising the amino acid sequence of SEQ ID NO: 8,

[0181] The VL comprises:

[0182] d) a LCDR1 region comprising the amino acid sequence of SEQ ID NO: 10,

[0183] e) a LCDR2 region comprising the amino acid sequence of SEQ ID NO: 11, and

[0184] f) a LCDR3 region comprising the amino acid sequence of SEQ ID NO:13.

[0185] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising a heavy chain variable region (VH), the heavy chain variable region comprising an amino acid sequence selected from SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19 having at least 95%, 96%, 97%, 98%, 99% or 100% identity. In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising a light chain variable region (VL), the light chain variable region comprising an amino acid sequence having at least 95%, 96%, 97%, 98%, 99% or 100% identity to an amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 21. In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising: a heavy chain variable region (VH), wherein the heavy chain variable region comprises an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19, and a light chain variable region (VL), wherein the light chain variable region comprises an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 21. In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising a heavy chain variable region (VH), the heavy chain variable region comprising an amino acid sequence selected from SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19. In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising a light chain variable region (VL), the light chain variable region comprising an amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 21.In one embodiment, the present disclosure provides an isolated human antibody or an antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising: a heavy chain variable region (VH), wherein the heavy chain variable region comprises an amino acid sequence selected from SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19, and a light chain variable region (VL), wherein the light chain variable region comprises the amino acid sequence SEQ ID NO: 20 or SEQ ID NO: 21.

[0186] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for Cluster of Differentiation 3 (CD3), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH and VL are selected from:

[0187] i. a VH comprising the amino acid sequence of SEQ ID NO: 25 and a VL comprising the amino acid sequence of SEQ ID NO: 20, and

[0188] ii. VH comprising the amino acid sequence of SEQ ID NO:14 and VL comprising the amino acid sequence of SEQ ID NO:26.

[0189] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for Cluster of Differentiation 3 (CD3), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH and VL are selected from:

[0190] i. a VH comprising the amino acid sequence of SEQ ID NO: 14 and a VL comprising the amino acid sequence of SEQ ID NO: 20,

[0191] ii. a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0192] iii. a VH comprising the amino acid sequence of SEQ ID NO: 16 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0193] iv. a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0194] v. a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 21, and

[0195] vi. VH comprising the amino acid sequence of SEQ ID NO:19 and VL comprising the amino acid sequence of SEQ ID NO:21.

[0196] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:14 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:20.

[0197] In one embodiment, the present disclosure provides an isolated human antibody or an antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:15 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:21.

[0198] In one embodiment, the present disclosure provides an isolated human antibody or an antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:16 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:21.

[0199] In one embodiment, the present disclosure provides an isolated human antibody or an antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:17 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:21.

[0200] In one embodiment, the present disclosure provides an isolated human antibody or an antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:18 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:21.

[0201] In one embodiment, the present disclosure provides an isolated human antibody or an antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), comprising: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 21.

[0202] In one aspect, the human antibody or antigen binding fragment thereof that is specifically directed against CD3 is a monoclonal antibody or antigen binding fragment. In another aspect, the human antibody or antigen binding fragment thereof that is specifically directed against CD3 is a recombinant antibody or antigen binding fragment. In one aspect, the human antibody or antigen binding fragment thereof that is specifically directed against CD3 is a synthetic antibody or antigen binding fragment. In one aspect of the present disclosure, the human antibody or antigen binding fragment thereof that is specifically directed against CD3 is a full-length IgG of an isotype selected from IgG1, IgG2, IgG3, and IgG4.

[0203] Specificity

[0204] In one embodiment, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3). In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure is specific for human CD3. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure is specific for cynomolgus monkey CD3. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure is specific for human and cynomolgus monkey CD3.

[0205] In one aspect of the present disclosure, the human antibody or antigen-binding fragment thereof specifically directed to CD3 according to the separation of the present disclosure is specific for human CD3ε. In one aspect, the human antibody or antigen-binding fragment thereof specifically directed to CD3 according to the separation of the present disclosure is specific for cynomolgus monkey CD3ε. In one aspect, the human antibody or antigen-binding fragment thereof specifically directed to CD3 according to the separation of the present disclosure is specific for human and cynomolgus monkey CD3ε. In one aspect, the human antibody or antigen-binding fragment thereof specifically directed to human and cynomolgus monkey CD3ε according to the separation of the present disclosure is specific for human and cynomolgus monkey CD3ε.

[0206] In one aspect, the present disclosure provides a human antibody or antigen-binding fragment thereof specifically for human CD3 according to the present disclosure, wherein the antibody or its antigen-binding fragment cross-reactively binds to cynomolgus monkey CD3. In one aspect, the present disclosure provides a human antibody or antigen-binding fragment thereof specifically for human CD3ε, wherein the antibody or its antigen-binding fragment cross-reactively binds to cynomolgus monkey CD3ε. In one aspect, the present disclosure provides a human antibody or antigen-binding fragment thereof specifically for CD3, wherein the antibody or its antigen-binding fragment specifically binds to human CD3ε. In one aspect of the present disclosure, a human antibody or its antigen-binding fragment specifically for CD3 that is separated specifically binds to human and cynomolgus monkey CD3ε.

[0207] In one aspect, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for human CD3, wherein the human CD3 is human CD3 epsilon comprising the amino acid sequence of SEQ ID NO: 45 or SEQ ID NO: 46. In one aspect, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for human CD3, wherein the isolated human antibody or antigen-binding fragment thereof specifically binds to a human CD3 epsilon polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 41 and SEQ ID NO: 43.

[0208] In one aspect, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for human CD3, wherein the cynomolgus monkey CD3 is a cynomolgus monkey CD3 epsilon comprising the amino acid sequence of SEQ ID NO: 47 or SEQ ID NO: 48. In one aspect, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for human CD3, wherein the isolated human antibody or antigen-binding fragment thereof specifically binds to a cynomolgus monkey CD3 epsilon polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 42, and SEQ ID NO: 44.

[0209] In one aspect, the present disclosure provides a human antibody or antigen-binding fragment thereof that is isolated and specific for human CD3, wherein the isolated human antibody or antigen-binding fragment thereof specifically binds to a polypeptide comprising an amino acid sequence selected from SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 42 and SEQ ID NO: 44. In one aspect of the present disclosure, the isolated human antibody or antigen-binding fragment thereof specifically for CD3 according to the present disclosure specifically binds to the extracellular region of human CD3ε. In one aspect, the isolated human antibody or antigen-binding fragment thereof specifically for CD3 according to the present disclosure specifically binds to the extracellular region of human and cynomolgus CD3ε. In one aspect of the present disclosure, the extracellular region of human CD3ε comprises the amino acid sequence SEQID NO: 46. In another aspect, the extracellular region of cynomolgus CD3ε comprises the amino acid sequence SEQ ID NO: 48. In one aspect, the present disclosure relates to an isolated human antibody or antigen-binding fragment thereof, which is specific for a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43 and SEQ ID NO: 44. In one aspect, the present disclosure relates to an isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure, which specifically binds to a polypeptide encoded by SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 41 or SEQ ID NO: 43 and a polypeptide encoded by SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 42 or SEQ ID NO: 44.

[0210] In one aspect of the present disclosure, the isolated human antibody or antigen-binding fragment thereof specific for CD3 comprises

[0211] i. The heavy chain variable region (VH), which comprises

[0212] (a) HCDR1 comprising the amino acid sequence GFSFGSHYMS (SEQ ID NO: 1),

[0213] (b) a HCDR2 comprising the amino acid sequence NINQIGYSSYYVESVKG (SEQ ID NO: 2), NINQIGYSSYYGESVKG (SEQ ID NO: 3) or NINQIGYSSYYEESVKG (SEQ ID NO: 4), and

[0214] (c) a HCDR3 comprising the amino acid sequence GYSAEFAHRSGLDV (SEQ ID NO: 5), GYSDEFATRSGLDV (SEQ ID NO: 6), GYSEEFAHRSGLDV (SEQ ID NO: 7), GYSDEFAKRSGLDV (SEQ ID NO: 8) or GYSDEFAHRSGLDV (SEQ ID NO: 9), and

[0215] ii. a variable light chain region (VL), which comprises

[0216] (d) LCDR1 comprising the amino acid sequence SGSSSNIGSNYVY (SEQ ID NO: 10),

[0217] (e) LCDR2 comprising the amino acid sequence RNNQRPS (SEQ ID NO: 11), and

[0218] (f) LCDR3 comprising the amino acid sequence AGWSRSLHGAV (SEQ ID NO: 12) or AGWSRELHGAV (SEQ ID NO: 13).

[0219] In one aspect of the present disclosure, the isolated human antibody or antigen-binding fragment thereof specific for CD3 comprises VH and VL, wherein the VH and VL are selected from:

[0220] i. a VH comprising the amino acid sequence of SEQ ID NO: 14 and a VL comprising the amino acid sequence of SEQ ID NO: 20,

[0221] ii. a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0222] iii. a VH comprising the amino acid sequence of SEQ ID NO: 16 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0223] iv. a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0224] v. a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 21, and

[0225] vi. VH comprising the amino acid sequence of SEQ ID NO:19 and VL comprising the amino acid sequence of SEQ ID NO:21.

[0226] dynamics

[0227] In one aspect, the present disclosure relates to an isolated human antibody or antigen-binding fragment thereof specific for human CD3, wherein the antibody or antigen-binding fragment thereof has a monovalent affinity for a human CD3ε peptide comprising SEQ ID NO: 41 and / or SEQ ID NO: 43, and its K D The K of an antibody comprising VH and VL comprising the amino acid sequences of SEQ ID NO: 25 and SEQ ID NO: 26, respectively. D Relatively low.

[0228] In one aspect, the present disclosure relates to an isolated human antibody or antigen-binding fragment thereof specific for human CD3, wherein the antibody or antigen-binding fragment thereof has a monovalent affinity for a human CD3ε peptide comprising SEQ ID NO: 41 and / or SEQ ID NO: 43, and its K D 10 nM or less, e.g., 8 nM or less, 7 nM or less, 6 nM or less, 5 nM or less, 4 nM or less, 3 nM or less, 2 nM or less, 1 nM or less, 0.1 nM or less, 0.2 nM, or 0.1 nM or less.

[0229] In one aspect, the present disclosure relates to an isolated human antibody or antigen-binding fragment thereof specific for human CD3, wherein the antibody or antigen-binding fragment thereof has a monovalent affinity for a human CD3 epsilon peptide comprising SEQ ID NO: 41 or SEQ ID NO: 43, and its K D It is about 10nM, about 9nM, about 7nM, about 6nM, about 5nM, about 4nM, about 3nM, about 2nM, about 1nM, about 0.9nM, about 0.8nM, about 0.7nM, about 0.6nM, about 0.5nM, about 0.4nM, about 0.3nM, about 0.2nM, about 0.1nM.

[0230] In one aspect, the present disclosure relates to an isolated human antibody or antigen-binding fragment thereof specific for CD3, wherein the antibody or antigen-binding fragment thereof has a monovalent affinity for a human CD3ε polypeptide comprising SEQ ID NO: 41 or SEQ ID NO: 34, and its K D Between 0.1nM and 10nM.

[0231] In certain aspects, the monovalent affinity is determined for scFv, Fv or Fab. In one aspect, the monovalent affinity is determined as described in Example 2.1, Example 3.4, Example 4.4 or Example 4.8 herein. In one aspect, the monovalent affinity is determined in an antibody format as described in Example 2, Example 3 or Example 4 herein.

[0232] In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3) comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:15, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:21.

[0233] Cell binding

[0234] In one aspect, the present disclosure relates to an isolated human antibody or antigen-binding fragment thereof specific for human CD3, wherein the antibody or antigen-binding fragment thereof specifically binds to human Jurkat cells (ATCC #TIB-152), whose EC 50 The concentration is between 40 nM and 120 nM, for example between 1 nM and 10 nM.

[0235] In one aspect, the present disclosure relates to an isolated human antibody or antigen-binding fragment thereof specific for human CD3, wherein the antibody or antigen-binding fragment thereof specifically binds to human Jurkat cells (ATCC #TIB-152), whose EC 50 The concentration is about 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 20 nM, about 30 nM, about 40 nM, about 50 nM, about 60 nM, about 70 nM, about 80 nM, about 90 nM, about 100 nM.

[0236] In one aspect, the EC 50 The concentration is determined in a FACS assay as described in Example 2.2 or Example 3.5 herein. In one aspect, the EC 50 The concentration is determined in Fab format. 50 The concentration is determined in the form of an antibody Fv. 50 The concentration is determined for the bispecific antibody format according to Example 2 or Example 3, which comprises the isolated human antibody specific for human CD3 or an antigen-binding fragment thereof according to the present disclosure.

[0237] In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3) comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:15, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:21.

[0238] ELISA binding

[0239] In one aspect, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, which specifically binds to a recombinant human CD3ε polypeptide comprising SEQ ID NO: 41 or SEQ ID NO: 43, wherein the EC 50 The concentration is between 1-40 nM, preferably between 1-15 nM. In one aspect, the isolated human antibody or antigen-binding fragment thereof specifically binds to a recombinant human CD3ε polypeptide having SEQ ID NO: 41 or SEQ ID NO: 43, and its EC 50 The concentration is less than 40 nM, preferably less than 15 nM. In one aspect, the antibody or antigen-binding fragment thereof specifically binds to a recombinant human CD3ε polypeptide having SEQ ID NO: 41 or SEQ ID NO: 43, and its EC 50 The concentration is the EC of an antibody or antigen-binding fragment thereof specific for CD3 comprising the VH of SEQ ID NO: 14 and the VL of SEQ ID NO: 20 or the VH of SEQ ID NO: 25 and the VL of SEQ ID NO: 26. 50 The concentration may be about 0.5 times lower, about 1 times lower, about 1.5 times lower, about 2 times lower, about 2.5 times lower, or about 3 times lower.

[0240] In one aspect, the EC 50 The concentration is determined as described in Example 4.7 herein. In one aspect, the EC 50 The concentration is determined in an ELISA assay. 50 Concentrations are determined for antibody Fv. In one aspect, the EC 50 The concentration was determined for the bispecific antibody format according to Example 4, which comprises the isolated human antibody specific for human CD3 or an antigen-binding fragment thereof according to the present disclosure.

[0241] In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3) comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:15, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:21.

[0242] Security

[0243] In one aspect, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, wherein the antibody or antigen-binding fragment thereof induces less upregulation of CD69 expression on CD4+ and / or CD8+ T cells compared to an isolated human antibody or antigen-binding fragment thereof specific for CD3 comprising VH of SEQ ID NO: 14 and VL of SEQ ID NO: 20.

[0244] In one aspect, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof, which specifically binds to CD3 expressed on CD4+ and / or CD8+ T cells and induces a lower amount of upregulated CD69 expression in CD4+ and / or CD8+ T cells compared to an antibody or antigen-binding fragment thereof specific for CD3 comprising the VH of SEQ ID NO: 14 and the VL of SEQ ID NO: 20.

[0245] In certain aspects, the upregulation of CD69 on CD4+ and / or CD8+ T cells is determined by the method described in Example 4.13 herein. In certain aspects, the upregulation of CD69 is determined for the bispecific antibody according to Example 4, the bispecific antibody comprising a human antibody or antigen-binding fragment thereof specifically directed to CD3 separated according to the present disclosure. In one aspect, the antibody is a bispecific antibody. In one aspect, the bispecific antibody monovalently binds to CD3 expressed on CD4+ and / or CD8+ positive T cells. In one aspect, the upregulation of CD69 is determined for an Fv fragment. In certain aspects, the antibody or antigen-binding fragment thereof specifically directed to CD3 is an antibody or antigen-binding fragment thereof listed in Table 8.

[0246] In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3) comprises: a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:15, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:21.

[0247] De-immunization

[0248] T cell epitopes are specific peptide sequences in a polypeptide sequence that can bind to MHC class II molecules with reasonable efficiency, or bind strongly to the T cell receptor of a species in the form of a peptide:MHC complex to receive (therapeutic) proteins or polypeptides, or they show the ability to stimulate T cells through presentation on MHC class II. (Potential) T cell epitopes can be measured by any computational or physical method to establish MHC binding. However, it is understood that some peptides found to bind to MHC class II molecules are recognized as "self" in the organism to which the protein is administered, and therefore do not cause an immune response. For example, such peptides are found in the variable region protein sequences of human germline immunoglobulins. By removing potential T cell epitopes present in parental human antibodies specific for CD3, the present disclosure adopts a method for designing improved human antibodies specific for CD3. This involves selecting amino acid substitutions so as to remove identified T cell epitopes, and testing a series of variant molecules with different amino acid substitutions. The principle of the present disclosure is to change the primary CDR sequence of human CD3-specific antibodies by identifying potential T cell epitopes and their subsequent changes within CDRs to eliminate such potential T cell epitopes. The presence of T cell epitopes in the primary sequence of a therapeutic antibody can be analyzed by any suitable method. In the methods disclosed herein, computational screening methods such as Lonza (Epibase TM , Epibase version: v3.0, WO 2003 / 105058).

[0249] In one aspect, the present disclosure provides an isolated deimmunized human antibody or antigen-binding fragment thereof specific for CD3. In one aspect, the present disclosure provides an antibody or antigen-binding fragment thereof specific for CD3, which is an isolated deimmunized human antibody or antigen-binding fragment thereof specific for CD3. In one aspect, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, which is less immunogenic or non-immunogenic in humans than an antibody or antigen-binding fragment thereof specific for CD3 comprising a VH of SEQ ID NO: 14 and a VL of SEQ ID NO: 20.

[0250] In one aspect, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, wherein the antibody or antigen-binding fragment has a reduced risk of eliciting an immune response or immunogenic reaction in a human. In one aspect, the present disclosure provides an isolated human antibody or antigen-binding fragment thereof specific for CD3, wherein the antibody or antigen-binding fragment has a reduced risk of eliciting a human anti-human antibody response in a human.

[0251] In one aspect, the antibody or antigen-binding fragment thereof, once administered to a human, has a reduced risk of eliciting an immune response or immunogenic response in the human. In one aspect, the reduced risk refers to the risk of eliciting an immune response or immunogenic response in a human comprising a VH of SEQ ID NO: 14 and a VL of SEQ ID NO: 20. In one aspect of the present disclosure, the reduced risk of eliciting an immune response or immunogenic response in a human is determined as described in Example 4 herein. In one aspect of the present disclosure, the reduced risk is determined for VH and / or VL of a human antibody or antigen-binding fragment thereof specifically for CD3 according to the present disclosure.

[0252] In one aspect of the disclosure, the risk or reduced risk is provided as a numerical value determined for a T cell epitope, risk score, absolute score, H-line, absolute H-line, H-score and absolute H-score and / or hotspot, all of which are as defined herein. In one aspect of the disclosure, the risk or reduced risk refers to the risk determined for a human antibody or antigen binding fragment thereof comprising the VH of SEQ ID NO: 14 and the VL of SEQ ID NO: 20. In one aspect, the in silico T cell epitope screening tool Epibase based on WO2003 / 105058 (incorporated herein in its entirety) is used. TM, Epibase Version: v3.0 (Lonza) The values ​​determined for T cell epitopes, risk scores, absolute scores, H-lines, absolute H-lines, H-scores and absolute H-scores and / or hotspots. In one aspect, the allele set is the major Caucasian DRB1 allele. In one aspect, the risk is determined for different isotypes of the Caucasian DRB1 allele. In one aspect, the filter set is for human antibody germline sequences. In one aspect, the risk is determined by excluding human antibody germline sequences present in VH and / or VL of human antibodies or antigen-binding fragments thereof specifically for CD3 according to the present disclosure. In one aspect, the risk is determined for HCDR1, HCDR2, HCDR3 and LCDR3 regions of human antibodies or antigen-binding fragments thereof specifically for CD3 according to the present disclosure. In one aspect, the risk excludes the risk of human antibody germline sequences eliciting an immune response in humans. In one aspect, the selected population is Caucasian. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a reduced risk of eliciting an immune response or immunogenic response in humans of the Caucasian population. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a reduced risk of eliciting an immune response or immunogenic response in humans of the Caucasian population compared to the risk of an isolated human antibody or antigen-binding fragment thereof specific for CD3 comprising VH of SEQ ID NO: 14 and VL of SEQ ID NO: 20.

[0253] In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VH with an absolute score as determined herein in the range of about 380-450, preferably in the range of about 390-425. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VH with an absolute score of less than 440, less than 430, less than 420, less than 410, less than 400, less than 395. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VH with a reduced absolute score compared to the VH comprising SEQ ID NO: 14. In one aspect, the reduced absolute score reduction is greater than 200, such as greater than 210, 215, 220, 230, 235, 240, 245 or 250.

[0254] In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VH with an absolute H-score in the range of about 330-370, preferably about 335-365. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VH with an absolute H-score of about 335 or 365. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VH with an absolute H-score of less than 370, less than 364, less than 360, less than 355, less than 350, less than 345, less than 340 or less than 335. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VH with a reduced absolute H-score compared to a VH comprising SEQ ID NO: 14. In one aspect, the reduced absolute H-score is reduced by more than 200, such as more than 210, 215, 220, 230, 235, 240, 245 or 250.

[0255] In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VH with an absolute H-line of 14. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VH with a reduced absolute H-line compared to the VH comprising SEQ ID NO: 14. In one aspect, the reduced absolute H-line is reduced by 11. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VH with an absolute hotspot of 4. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VH with a reduced absolute hotspot compared to the VH comprising SEQ ID NO: 14. In one aspect, the reduced absolute hotspot is reduced by 2. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VL with an absolute score and / or an absolute H-score of 62. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VL with a reduced absolute score and / or absolute H-score compared to the VH comprising SEQ ID NO: 14. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VL with an absolute H-score of 2. In one aspect, the isolated human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure has a VL with an absolute hotspot of 0.

[0256] In one embodiment, the isolated human antibody or antigen-binding fragment thereof specific for CD3 comprises VH and VL, wherein VH and VL are selected from:

[0257] i. a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0258] ii. a VH comprising the amino acid sequence of SEQ ID NO: 16 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0259] iii. a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0260] iv. a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 21, and

[0261] v. VH comprising the amino acid sequence of SEQ ID NO:19 and VL comprising the amino acid sequence of SEQ ID NO:21.

[0262] Multispecific Antibodies

[0263] The isolated human antibodies specific for CD3 or antigen-binding fragments thereof according to the present disclosure are preferably used in the form of bispecific or multispecific antibodies to target cytotoxic T cells expressing CD3 and stimulate cytotoxic T cell activation, for example, in cases where T cell-mediated killing of specific cell types (e.g., tumor cells) is beneficial or desirable.

[0264] According to the separation of the present disclosure, the specific human antibody or its antigen-binding fragment for CD3 can be connected or co-expressed with another functional molecule (e.g., another peptide or protein). In one aspect, the present disclosure relates to a human antibody or its antigen-binding fragment for separation specifically for CD3, wherein the antibody or its antigen-binding fragment is fused with a heterologous protein or polypeptide. In one aspect, the present disclosure relates to a fusion protein, which comprises a human antibody or its antigen-binding fragment for separation specifically for CD3 and a heterologous protein or polypeptide according to the present disclosure. For example, an antibody or its antigen-binding fragment can be functionally connected (e.g., by chemical coupling, gene fusion, non-covalent binding or other means) to one or more other molecular entities, such as another antibody or its antigen-binding fragment, to produce a bispecific or multispecific antibody with a second or optional third binding specificity. Bispecific or multispecific antibodies capable of binding to two or more antigens are of great significance for therapeutic applications. In another aspect, the present disclosure provides a human antibody or its antigen-binding fragment for separation specifically for CD3, wherein the antibody is a monospecific, bispecific or multispecific antibody or its antigen-binding fragment. A multispecific antibody may comprise antibodies or antigen-binding fragments thereof that are specific for different epitopes on the same target antigen, or may comprise antibodies or antigen-binding fragments thereof that are specific for more than one target antigen. In the context of bispecific or multispecific antibodies according to the present disclosure, the cell surface target antigen may be a tumor-associated antigen (TAA). Non-limiting examples of tumor-associated antigens include, for example, antigens expressed on the surface of tumors or cancer cells. Exemplary multispecific antibody formats that can be used in the context of the present disclosure include, but are not limited to, for example, scFv-based or double-chain antibody bispecific formats, IgG-scFv fusion, dual variable domains (DVD)-Ig, Quadroma, knob-into-hole, common light chain (e.g., common light chain with knob-into-hole, etc.), CrossMab, CrossFab, (SEED) body, leucine zipper, Duobody, IgG1 / IgG2, dual-acting Fab (DAF)-IgG, Mab2 bispecific formats (see, e.g., Klein et al. 2012, mAbs 4:6, 1-11) and half antibodies (see, e.g., Stuhler et al. Nat Commun. 2019; 10:5387). Preferably, the human antibody or antigen-binding fragment thereof separated according to the present disclosure specifically for CD3 is used in the form described in Example 3 or Example 5 herein or WO 2020 / 115115.

[0265] In one aspect, the present disclosure provides a bispecific or multispecific antibody, comprising an antigen-binding fragment of a human antibody specifically directed against CD3 according to the present disclosure and a second antigen-binding fragment of a second antibody that binds to a different antigen from the first antigen-binding fragment. In one aspect of the present disclosure, the second antigen-binding fragment binds to a cell surface antigen. In one aspect, the cell surface target antigen is a tumor-associated antigen. In one aspect, the first antigen-binding fragment binds to CD3 present or expressed on an immune effector cell. In one aspect, the immune effector cell is a T cell. In one aspect, the T cell is a cytotoxic T cell. In one aspect, the present disclosure provides a bispecific or multispecific antibody, comprising a human antibody or an antigen-binding fragment thereof specifically directed against CD3 according to the present disclosure, wherein the bispecific or multispecific antibody mediates redirected T cell killing of target antigen-expressing cells. In certain aspects, the target cell killing can be determined by the methods described herein, such as described in Example 4.12.

[0266] In one aspect of the present disclosure, the bispecific or multispecific antibodies according to the present disclosure specifically bind CD3 expressed on T cells and a second antigen present on cells other than T cells. In some aspects, the bispecific or multispecific antibodies activate T cells after binding CD3 expressed on T cells and a second antigen present on target cells other than T cells. In some aspects, activated T cells can exert cytotoxic effects and / or apoptotic effects on another cell. In one aspect, the present disclosure provides bispecific or multispecific antibodies comprising human antibodies or antigen-binding fragments thereof specifically for CD3 according to the present disclosure, wherein in the presence of cell surface target antigen expressing cells, the bispecific or multispecific antibodies induce human T cell proliferation after binding CD3 expressed on T cells and binding cell surface target expressing cells.

[0267] Joint Optimization

[0268] In one aspect, the bispecific antibodies according to the present disclosure consist of three Fv regions. This is achieved by using a conventional immunoglobulin (e.g., IgG) antibody structure (two heavy chains associated with two light chains to form two Fv regions) that incorporates an additional Fv region between the two Fab arms and the Fc portion of the conventional immunoglobulin structure. In one aspect, the bispecific antibodies according to the present disclosure have Figure 2 The general structure depicted in .

[0269] In one aspect, the present disclosure provides a bispecific antibody comprising

[0270] a) a first Fab comprising a first Fv region that specifically binds to a first antigen,

[0271] b) a second Fv region that specifically binds to a second antigen, and

[0272] c) a second Fab comprising a third Fv region that specifically binds to a third antigen, and

[0273] d) an Fc region consisting of a first and a second Fc region subunit, wherein

[0274] i. The C-terminus of the first Fab heavy chain is fused to the N-terminus of the VH or VL of the second Fv region via a first peptide linker, wherein

[0275] ii. The C-terminus of the VH or VL of the second Fv region is fused to the N-terminus of the first Fc region subunit via a second peptide linker, wherein

[0276] iii. The N-terminus of the second Fc region subunit is fused to the C-terminus of the complementary variable domain of the second Fv region via a fourth peptide linker, and wherein

[0277] iv. The C-terminus of the second Fab heavy chain is fused to the N-terminus of the VH or VL of the second Fv region via a third peptide linker, provided that the first and second Fab are fused to different variable regions of the second Fv region.

[0278] In one aspect, the C-terminus of the CH1 domain of the first Fab is fused to the N-terminus of the VH or VL of the second Fv region through a first peptide linker, provided that the first and second Fabs are fused to different variable domains of the second Fv region. In one aspect, the C-terminus of the CH1 domain of the first Fab is fused to the N-terminus of the VH of the second Fv region through a first peptide linker, provided that the first and second Fabs are fused to different variable domains of the second Fv region. In one aspect, the C-terminus of the CH1 domain of the first Fab is fused to the N-terminus of the VL of the second Fv region through a first peptide linker, provided that the first and second Fabs are fused to different variable domains of the second Fv region.

[0279] In one aspect, the C-terminus of the CH1 domain of the second Fab is fused to the N-terminus of the VH or VL of the second Fv region through a third peptide linker, provided that the first and second Fabs are fused to different variable domains of the second Fv region. In one aspect, the C-terminus of the CH1 domain of the second Fab is fused to the N-terminus of the VH of the second Fv region through a third peptide linker, provided that the first and second Fabs are fused to different variable domains of the second Fv region. In one aspect, the C-terminus of the CH1 domain of the second Fab is fused to the N-terminus of the VL of the second Fv region through a third peptide linker, provided that the first and second Fabs are fused to different variable domains of the second Fv region.

[0280] In one aspect, the C-terminus of the heavy chain of the first Fab is fused to the N-terminus of the VL of the second Fv region through a first peptide linker, and the C-terminus of the heavy chain of the second Fab is fused to the N-terminus of the VH of the second Fv region through a third peptide linker. In one aspect, the C-terminus of the heavy chain of the first Fab is fused to the N-terminus of the VH of the second Fv region through a first peptide linker, and the C-terminus of the heavy chain of the second Fab is fused to the N-terminus of the VL of the second Fv region through a third peptide linker.

[0281] In one aspect, a bispecific antibody according to the present disclosure comprises four polypeptides, wherein

[0282] a) the first polypeptide comprises the light chain of a first Fab,

[0283] b) the second polypeptide comprises, from its N-terminus to its C-terminus

[0284] i. the heavy chain of the first Fab,

[0285] ii. a first peptide linker,

[0286] iii. VL of the second Fv region,

[0287] iv. a second peptide linker, and

[0288] v. First Fc region subunit

[0289] c) the third polypeptide comprises, from its N-terminus to its C-terminus

[0290] i. the heavy chain of the second Fab,

[0291] ii. a third peptide linker,

[0292] iii. VH of the second Fv region,

[0293] iv. Fourth Peptide Linker

[0294] v. a second Fc region subunit, and

[0295] d) the fourth polypeptide comprises the light chain of the second Fab.

[0296] In one aspect, a bispecific antibody according to the present disclosure comprises four polypeptides, wherein

[0297] a) the first polypeptide comprises the light chain of a first Fab,

[0298] b) the second polypeptide comprises, from its N-terminus to its C-terminus

[0299] i. the heavy chain of the first Fab,

[0300] ii. a first peptide linker,

[0301] iii. VH of the second Fv region,

[0302] iv. a second peptide linker, and

[0303] iii. First Fc region subunit

[0304] c) the third polypeptide comprises, from its N-terminus to its C-terminus

[0305] i. the heavy chain of the second Fab,

[0306] ii. a third peptide linker,

[0307] iii. VL of the second Fv region,

[0308] iv. a fourth peptide linker, and

[0309] v. Second Fc region subunit

[0310] d) the fourth polypeptide comprises the light chain of the second Fab.

[0311] In one aspect of the present disclosure, the first, second, third and fourth peptide linkers are selected from the following amino acid sequences:

[0312]

[0313] In one aspect of the disclosure, the second and fourth peptide linkers are fused to the amino acid sequence DKTHTCPPCP (SEQ ID NO: 38) at the C-terminus. In one aspect of the disclosure, the second and fourth peptide linkers further comprise the amino acid sequence DKTHTCPPCP (SEQ ID NO: 38) at the C-terminus.

[0314] In one aspect of the present disclosure, the second and fourth peptide linkers are selected from the following amino acid sequences:

[0315]

[0316] In one aspect of the present disclosure,

[0317] a) the first and third peptide linkers comprise the amino acid sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:31), the second peptide linker comprises the amino acid sequence PKAAP (SEQ ID NO:36), and the fourth peptide linker comprises the amino acid sequence ASTKGP (SEQ ID NO:37), or

[0318] b) the first and third peptide linkers comprise the amino acid sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:31), and the second and fourth peptide linkers comprise the amino acid sequence AQPAAPAPDAHEAPAPAQGS (SEQ ID NO:33), or

[0319] c) the first and third peptide linkers comprise the amino acid sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:31), the second peptide linker comprises the amino acid sequence PKAAPSVTLFPPSSEELQAN (SEQ ID NO:34), and the fourth peptide linker comprises the amino acid sequence ASTKGPSVFPLAPSSKSTSG (SEQ ID NO:35), or

[0320] d) the first and third peptide linkers comprise the amino acid sequence AHPAAPAPAHPAAPAPAHGH (SEQ ID NO:32), the second peptide linker comprises the amino acid sequence PKAAPSVTLFPPSSEELQAN (SEQ ID NO:34), and the fourth peptide linker comprises the amino acid sequence ASTKGPSVFPLAPSSKSTSG (SEQ ID NO:35), or

[0321] e) the first and third peptide linkers comprise the amino acid sequence AQPAAPAPDAHEAPAPAQGS (SEQ ID NO:33), the second peptide linker comprises the amino acid sequence PKAAPSVTLFPPSSEELQAN (SEQ ID NO:34), and the fourth peptide linker comprises the amino acid sequence ASTKGPSVFPLAPSSKSTSG (SEQ ID NO:35), or

[0322] f) the first and third peptide linkers comprise the amino acid sequence GGSGGSGGS (SEQ ID NO:30), the second peptide linker comprises the amino acid sequence PKAAPSVTLFPPSSEELQAN (SEQ ID NO:34), and the fourth peptide linker comprises the amino acid sequence ASTKGPSVFPLAPSSKSTSG (SEQ ID NO:35).

[0323] In one aspect of the present disclosure,

[0324] a) the first and third peptide linkers comprise the amino acid sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:31), the second peptide linker comprises the amino acid sequence PKAAPDKTHTCPPCP (SEQ ID NO:76), and the fourth peptide linker comprises the amino acid sequence ASTKGPDKTHTCPPCP (SEQ ID NO:77), or

[0325] b) the first and third peptide linkers comprise the amino acid sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:31), and the second and fourth peptide linkers comprise the amino acid sequence AQPAAPAPDAHEAPAPAQGSDKTHTCPPCP (SEQ ID NO:78), or

[0326] c) the first and third peptide linkers comprise the amino acid sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:31), the second peptide linker comprises the amino acid sequence PKAAPSVTLFPPSSEELQANDKTHTCPPCP (SEQ ID NO:79), and the fourth peptide linker comprises the amino acid sequence ASTKGPSVFPLAPSSKSTSGDKTHTCPPCP (SEQ ID NO:80), or

[0327] d) the first and third peptide linkers comprise the amino acid sequence AHPAAPAPAHPAAPAPAHGH (SEQ ID NO:32), the second peptide linker comprises the amino acid sequence PKAAPSVTLFPPSSEELQANDKTHTCPPCP (SEQ ID NO:79), and the fourth peptide linker comprises the amino acid sequence ASTKGPSVFPLAPSSKSTSGDKTHTCPPCP (SEQ ID NO:80), or

[0328] e) the first and third peptide linkers comprise the amino acid sequence AQPAAPAPDAHEAPAPAQGS (SEQ ID NO:33), the second peptide linker comprises the amino acid sequence PKAAPSVTLFPPSSEELQANDKTHTCPPCP (SEQ ID NO:79), and the fourth peptide linker comprises the amino acid sequence ASTKGPSVFPLAPSSKSTSGDKTHTCPPCP (SEQ ID NO:80), or

[0329] f) the first and third peptide linkers comprise the amino acid sequence GGSGGSGGS (SEQ ID NO:30), the second peptide linker comprises the amino acid sequence PKAAPSVTLFPPSSEELQANDKTHTCPPCP (SEQ ID NO:79), and the fourth peptide linker comprises the amino acid sequence ASTKGPSVFPLAPSSKSTSGDKTHTCPPCP (SEQ ID NO:80).

[0330] In one aspect of the present disclosure, the first and third peptide linkers comprise the amino acid sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 31), and the second and fourth peptide linkers comprise the amino acid sequence AQPAAPAPDAHEAPAPAQGS (SEQ ID NO: 33). In one aspect of the present disclosure, the first and third peptide linkers comprise the amino acid sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 31), and the second and fourth peptide linkers comprise the amino acid sequence AQPAAPAPDAHEAPAPAQGSDKTHTCPPCP (SEQ ID NO: 78).

[0331] In one aspect of the present disclosure, the second Fv region specifically binds to CD3. In one aspect, the second Fv is specific for CD3, particularly for human CD3, and more particularly for human CD3ε.

[0332] In one aspect of the present disclosure, the second Fv comprises

[0333] i. The heavy chain variable region (VH), which comprises

[0334] (a) a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence GFSFGSHYMS (SEQ ID NO: 1),

[0335] (b) a HCDR2 comprising the amino acid sequence NINQIGYSSYYVESVKG (SEQ ID NO: 2), NINQIGYSSYYGESVKG (SEQ ID NO: 3) or NINQIGYSSYYEESVKG (SEQ ID NO: 4), and

[0336] (c) a HCDR3 comprising the amino acid sequence GYSAEFAHRSGLDV (SEQ ID NO: 5), GYSDEFATRSGLDV (SEQ ID NO: 6), GYSEEFAHRSGLDV (SEQ ID NO: 7), GYSDEFAKRSGLDV (SEQ ID NO: 8) or GYSDEFAHRSGLDV (SEQ ID NO: 9), and

[0337] ii. a variable light chain region (VL), which comprises

[0338] (d) a light chain complementary determining region (LCDR) 1 comprising the amino acid sequence SGSSSNIGSNYVY (SEQ ID NO: 10),

[0339] (e) LCDR2 comprising the amino acid sequence RNNQRPS (SEQ ID NO: 11), and

[0340] (f) LCDR3 comprising the amino acid sequence AGWSRSLHGAV (SEQ ID NO: 12) or AGWSRELHGAV (SEQ ID NO: 13).

[0341] In one aspect of the present disclosure, the second Fv comprises a VH and a VL selected from:

[0342] i. a VH comprising the amino acid sequence of SEQ ID NO: 14 and a VL comprising the amino acid sequence of SEQ ID NO: 20,

[0343] ii. a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0344] iii. a VH comprising the amino acid sequence of SEQ ID NO: 16 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0345] iv. a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 21,

[0346] v. a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 21, and

[0347] vi. VH comprising the amino acid sequence of SEQ ID NO:19 and VL comprising the amino acid sequence of SEQ ID NO:21.

[0348] In one aspect of the present disclosure, the light chain of the first Fab or the second Fab comprises the VL and CL of the first Fab or the second Fab respectively. In one aspect of the present disclosure, the light chain of the first Fab and the second Fab is identical. In one aspect of the present disclosure, the heavy chain of the first Fab and the second Fab is identical. In one aspect of the present disclosure, the first Fab and the second Fab are identical.

[0349] In one aspect, the first and second Fc region subunits form an Fc region. In one aspect, the Fc region is an IgG1 Fc region. In one aspect, the IgG1 Fc region is a human IgG1 Fc region. In one aspect, the Fc region comprises one or more amino acid modifications that promote the combination of the first and second Fc region subunits. In one aspect, in the CH3 domain of the first Fc region subunit, the threonine residue at position 366 is replaced by a tryptophan residue (T366W), and the serine residue at position 354 is replaced by a cysteine ​​residue (S354C), and in the CH3 domain of the second Fc region subunit, the tyrosine residue at position 407 is replaced by a valine residue (Y407V), the threonine residue at position 366 is replaced by a serine residue (T366S), the leucine residue at position 368 is replaced by an alanine residue (L368A), and the tyrosine residue at position 349 is replaced by a cysteine ​​residue (Y349C), wherein numbering is performed according to the EU index. In one aspect of the present disclosure, the Fc region of the bispecific antibody according to the present disclosure has reduced binding affinity for Fc receptors and / or C1q and / or reduced effector function. In one aspect of the present disclosure, the Fc region comprises one or more amino acid mutations in each Fc region subunit, wherein the one or more amino acid mutations are selected from: L234A, L235E, G237A, A330S and P331S, wherein numbering is performed according to the EU index. In one aspect, in each Fc region subunit, at least 5 amino acid residues in the positions corresponding to positions L234, L235, G237, A330, P331 in human IgG1 numbered according to the EU index are mutated to A, E, A, S and S respectively.

[0350] In one aspect, the first antigen and the third antigen are the same. In one aspect, the first and third antigens are tumor-associated antigens. In one aspect, the first and third antigens are tumor-associated antigens, which are expressed on tumor cells or cancer cells. In one aspect, the second antigen is an immune cell-associated antigen. In one aspect, the second antigen is expressed on immune cells. In one aspect, the second antigen is expressed on immune effector cells. In one aspect, the second antigen is expressed on cytotoxic T cells. In one aspect, the second antigen is CD3. In one aspect, the second antigen is CD3ε. In one aspect, the second antigen is human CD3. In one aspect, the second antigen is human CD3ε. In one aspect, the bispecific antibody according to the present disclosure provides a bivalent binding to the first antigen and a monovalent binding to the second antigen. In one aspect, the bispecific antibody is a trivalent bispecific antibody.

[0351] effect

[0352] In certain aspects, the present disclosure provides a bispecific antibody according to the present disclosure, comprising a human antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure, wherein the bispecific antibody mediates killing of target antigen-expressing cells by target cells. In one aspect, the target cell killing is mediated in the presence of cytotoxic T cells. In certain aspects, the bispecific antibody comprises a second antigen-binding fragment of an antibody that specifically binds to a cell surface target antigen. In certain aspects, the target antigen is a tumor-associated antigen. In one aspect, the target antigen is HER2. In one aspect, the second antigen-binding fragment of the antibody binds to HER2 (UniProtKB-P04626). In one aspect, the target cell is a tumor cell or a cancer cell. In one aspect, the target cell is SKOV-3 SKBR3 or MCF-7 In certain aspects, target cell killing is determined by the methods described in Example 4.13 herein.

[0353] treat

[0354] In one aspect, the present disclosure provides a human antibody or an antigen-binding fragment thereof or a bispecific antibody according to the present disclosure that is separated and specifically directed to CD3 for use as a medicament. In one aspect, the present disclosure relates to a human antibody or an antigen-binding fragment thereof or a bispecific antibody according to the present disclosure that is separated and specifically directed to CD3 for use in the preparation or manufacture of a medicament. In one aspect, the present disclosure provides a human antibody or an antigen-binding fragment thereof or a bispecific antibody according to the present disclosure that is separated and specifically directed to CD3 for use in enhancing the immune function of a subject suffering from a cell proliferative disease.

[0355] In one aspect, the present disclosure provides a method for treating or delaying the progression of a cell proliferative disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a human antibody or antigen binding fragment thereof that is separated and specifically directed to CD3 or a bispecific antibody according to the present disclosure. In one aspect, the human antibody or antigen binding fragment thereof that is separated and specifically directed to CD3 or a bispecific antibody according to the present disclosure is used to treat a cell proliferative disease in a subject in need thereof or delay its progression. In one aspect, the cell proliferative disease is cancer. In one aspect, the cancer is selected from, but not limited to, esophageal cancer, gastric cancer, small intestine cancer, colorectal cancer, breast cancer, non-small cell lung cancer, non-Hodgkin's lymphoma (NHL), B cell lymphoma, B cell leukemia, multiple myeloma, renal cancer, prostate cancer, liver cancer, head and neck cancer, melanoma, ovarian cancer, mesothelioma, glioblastoma, germinal center B cell-like (GCB) DLBCL, activated B cell-like (ABC) DLBCL, follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), Waldenstrom's macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B-cell prolymphocytic leukemia, splenic marginal zone lymphoma, hairy cell leukemia, splenic lymphoma / leukemia, unclassifiable, splenic diffuse red pulp small B-cell lymphoma, hairy cell leukemia leukemia variants, Waldenstrom's macroglobulinemia, plasma cell myeloma, solitary plasmacytoma of bone, extraosseous plasmacytoma, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), nodal marginal zone lymphoma, nodal marginal zone lymphoma of children, follicular lymphoma of children, primary cutaneous follicle center lymphoma, T cell / histiocyte-rich large B cell lymphoma, primary DLBCL of the central nervous system, primary cutaneous DLBCL, leg type, EBV-positive DLBCL in the elderly, DLBCL associated with chronic inflammation LBCL, lymphomatoid granuloma, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, primary effusion lymphoma: unclassifiable B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, and unclassifiable B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma.

[0356] In one aspect, the present disclosure provides the use of a human antibody or its antigen-binding fragment or bispecific antibody separated specifically for CD3 according to the present disclosure for the manufacture of a medicament for treating a cell proliferative disease or delaying its progression. In one aspect, the present disclosure provides the use of a human antibody or its antigen-binding fragment or bispecific antibody separated specifically for CD3 according to the present disclosure for the manufacture of a medicament for enhancing the immune function of a subject suffering from a cell proliferative disease. In one aspect, the present disclosure provides a method of treating a subject in need using a human antibody or its antigen-binding fragment or bispecific antibody separated specifically for CD3 according to the present disclosure.

[0357] In one aspect, the isolated human antibody or antigen-binding fragment thereof or bispecific antibody specific for CD3 according to the present disclosure, or a pharmaceutical composition comprising the same, is administered subcutaneously, intravenously, intramuscularly, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally.

[0358] Composition

[0359] In one aspect, the present disclosure provides a pharmaceutical composition comprising a human antibody or antigen-binding fragment thereof or bispecific antibody specifically for CD3 according to the present disclosure and a pharmaceutically acceptable carrier or excipient. Such carriers or excipients are well known in the art, and those skilled in the art will find the most suitable formulation and route of administration for treating a subject with an antibody or antigen-binding fragment thereof according to the present disclosure. In one aspect, the present disclosure relates to the use of a pharmaceutical composition comprising a human antibody or antigen-binding fragment thereof or bispecific antibody specifically for CD3 according to the present disclosure in the preparation of a medicament for treating a disease. In one aspect, the present disclosure relates to the use of the pharmaceutical composition for treating a disease. In one aspect, the present disclosure provides a method for treating a cell proliferative disease in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a human antibody or antigen-binding fragment thereof or bispecific antibody specifically for CD3 according to the present disclosure. In one aspect, the present disclosure provides a pharmaceutical composition comprising a human antibody or antigen-binding fragment thereof or bispecific antibody specifically for CD3 according to the present disclosure and a combination of a second therapeutic agent. In one aspect, the second therapeutic agent is any agent that is advantageously combined with the human antibody or antigen-binding fragment thereof or bispecific antibody according to the present disclosure. The present disclosure provides a method of treating T cell activation using a human antibody or antigen-binding fragment thereof or bispecific antibody separated specifically for CD3 according to the present disclosure, wherein the method of treating comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a human antibody or antigen-binding fragment thereof or bispecific antibody separated specifically for CD3 according to the present disclosure. The present disclosure also provides a method of treating T cell killing redirected to cancer cells or tissues using a human antibody or antigen-binding fragment thereof or bispecific antibody separated specifically for CD3 according to the present disclosure, wherein the method of treating comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof or bispecific antibody according to the present disclosure.

[0360] Production

[0361] In another aspect, the disclosure relates to methods of producing an isolated human antibody specific for CD3 or an antigen-binding fragment thereof of any of the antibodies listed in Tables 5-7.

[0362] According to the disclosure of the invention, the coding sequence of the heavy chain and light chain of the antibody or antigen-binding fragment thereof specific for CD3 can be a recombinant DNA molecule, which is introduced into an expression vector by being operably connected to the necessary expression control region (e.g., regulatory region) required for gene expression. The technician will recognize that the polynucleotide encoding the heavy chain or light chain can be cloned into different vectors or cloned into the same vector. The vector can be introduced into a suitable host cell, such as a prokaryotic cell (e.g., bacteria) or a eukaryotic cell (e.g., yeast or mammal) cell (see, for example, "Current Protocol in Molecular Biology", Ausubel et al. (editor), Greene Publishing Assoc. and John Wiley Interscience, New York, 1989 and 1992). Many cloning vectors are known to those skilled in the art, and selecting a suitable cloning vector is a matter of choice. The gene can be placed under the control of a promoter, a ribosome binding site (for bacterial expression) and an optional operator (collectively referred to herein as "control" elements), so that the DNA sequence encoding the desired protein is transcribed into RNA in a host cell transformed by a vector comprising this expression construct. The coding sequence may or may not contain a signal peptide or a leader sequence. After expression in a host cell, the antibody or antigen-binding fragment thereof of the present invention is obtained. These steps can be implemented in different ways, as known to those skilled in the art. In general, such steps generally include transforming or transfecting a suitable host cell with a nucleic acid or a vector or infectious particles encoding an antibody molecule. In addition, such steps generally include culturing the host cell under conditions suitable for the reproduction (proliferation, growth) of the host cell, and carrying out a culturing step under conditions suitable for the production (expression, synthesis) of the encoded antibody or antigen-binding fragment. Cultivating host cells under conditions suitable for their proliferation or expression is generally completed in a culture medium containing components suitable for cell growth or induction of expression. In a particular aspect, the method for producing an antibody or antigen-binding fragment thereof of the present invention also includes a step of separating the produced antibody or antigen-binding fragment thereof from a host cell or culture medium. According to the selected expression system and host, the antibody or antigen-binding fragment thereof of the present invention is produced by culturing a host cell transformed by the above-mentioned expression vector under conditions expressing the target protein. The protein is then separated and purified from the host cell. If the expression system secretes the protein into the growth medium, the protein can be directly purified from the culture medium. If the protein is not secreted, the protein is isolated from the cell lysate or recovered from the cell membrane fraction. The selection of appropriate growth conditions and recovery methods are within the skill of the art. The antibodies or antigen-binding fragments thereof of the present disclosure may then be purified by a variety of techniques known to those skilled in the art. It should be noted that the Fab of the present disclosure is not a naturally occurring protein.The present disclosure also provides a recombinant expression vector capable of expressing a polypeptide comprising a heavy chain variable region or a light chain variable region of an antibody or antigen-binding fragment thereof specific for CD3 according to the present disclosure. For example, the present disclosure includes a recombinant expression vector encoding any of the amino acid sequences mentioned in Tables 5-7. The scope of the present disclosure also includes host cells into which such vectors have been introduced, and methods for producing antibodies or portions thereof by culturing host cells under conditions that allow the production of antibodies or antigen-binding fragments thereof and recovering the antibodies and antigen-binding fragments thereof so produced.

[0363] Antigen sequence

[0364] Table 2: Amino acid sequences of recombinant human and cynomolgus monkey CD3ε extracellular domain antigens fused to human IgG Fc or FLAG-tag used in this example.

[0365]

[0366] Antibody sequences

[0367] Table 3: Antibody variable light (VL) and variable heavy (VH) region sequences of the anti-HER2 antibody trastuzumab used in the examples of the present disclosure.

[0368]

[0369] Table 4: Progenitor CD3-specific antibodies CD3-MAB as described in PCT / EP2021 / 076052 GP The antibody variable light (VL) and variable heavy (VH) regions and CDR sequences (CDR sequences are provided in a combined Kabat+Chothia annotation).

[0370]

[0371] Table 5: Antibody VL, VH and CDR sequences of affinity-optimized antibodies CD3-MABopt_VL and CD3-MABopt_VH#1, both of which are ancestral antibodies CD3-MAB GP Derivatives of (CDRs are provided in combined Kabat+Chothia annotation).

[0372]

[0373]

[0374] Table 6: CD3-MAB containing affinity-optimized antibodies opt_VH#1 Variable heavy chain region (VH) and affinity-optimized antibody CD3-MAB opt_VLCross-cloning of the variable light chain region (VL) of CD3-MABopt_cc antibody VL, VH and CDR sequences (CDR sequences are provided in a combined Kabat+Chothia annotation)

[0375]

[0376] Table 7: Antibody VL, VH and CDR sequences of the deimmunized CDR variants of cross-cloned CD3-MABopt_cc (CDR sequences are provided in a combined Kabat+Chothia annotation)

[0377]

[0378]

[0379]

[0380] Table 8: Amino acid sequences of peptide linkers used in the bispecific 2+1 Fab2-Fv-Fc antibody according to Example 3.

[0381] Connectors Sequence [aa] SEQ ID NO: <![CDATA[(GGS)3]]> GGSGGSGGS 30 <![CDATA[(GGGGS)4 / (G4S)4]]> GGGGSGGGGSGGGGSGGGGS 31 20aa-PAH AHPAAPAPAHPAAPAPAHGH 32 20aa-PAPDA AQPAAPAPDAHEAPAPAQGS 33 20aa-Cλ PKAAPSVTLFPPSSEELQAN 34 20aa-CH1 ASTKGPSVFPLAPSSKSTSG 35 5aa-Cλ PKAAP 36 6aa-CH1 ASTKGP 37 Hinge shortened DKTHTCPPCP 38

[0382] Table 9: Amino acid sequences of peptide linkers used in the bispecific 2+1 Fab2-Fc-scFv antibody format according to Example 1.

[0383]

[0384] Table 10: Formation according to Example 1.2 and Figure 1 Amino acid sequences of exemplary polypeptides in the form of trivalent bispecific Fab2-Fc-scFv antibodies with bivalent binding to HER2 and monovalent binding to CD3 are shown in A. The bispecific antibody BissIg_08_#1 comprises the antibody variable domains of CD3-MABopt_VL, while BissIg_08_#2 comprises the antibody variable domains of MABopt_VH#1.

[0385]

[0386]

[0387] Table 11: Amino acid sequences of polypeptides forming source IgG1 molecules specific for HER2 (IgG1#) and CD3 (IgGopt_cc) in Example 2, used to generate bispecific antibodies BissIg_18_opt_cc# by Fab arm exchange. The CD3-specific IgG comprises the VL of CD3-MABopt_VL and the VH of MABopt_VH#1, thus reflecting the cross-cloned antibody CD3-MABopt_cc.

[0388]

[0389] Table 12: Formation according to Table 11, Example 2 and Figure 1 B shows the amino acid sequence of the polypeptide of the bivalent bispecific 1+1 antibody BissIg_18_opt_cc# (after the Fab arms of IgG#1 and IgGopt_cc are exchanged).

[0390]

[0391] Table 13: Formation of the method according to Example 3 (and Figure 2 The amino acid sequences of the polypeptides of the bispecific antibodies (shown in Table 23) with the improved peptide linker combinations listed in Table 23. All bispecific antibodies used the VH and VL of the cross-cloned antibody CD3-MABopt_cc.

[0392]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399] Table 14: Amino acid sequences of polypeptides used to form trivalent bispecific antibodies according to Example 4 using preferred deimmunized CD3-specific binding antibodies according to the present disclosure.

[0400]

[0401]

[0402]

[0403]

[0404]

[0405] Example

[0406] Example 1: Identification of affinity-optimized CD3-specific human antibodies

[0407] PCT / EP2021 / 076052 describes a fully human antibody CD3-MAB that cross-reacts with progenitor human cynomolgus monkey CD3 GP (comprising VH of SEQ ID NO: 25 and VL of SEQ ID NO: 26). Briefly, in order to identify CD3-MAB GP , using MorphoSys MorphoSys The library (Tiller et al., mAbs 5:3, 1-26; May / June (2013) and U.S. Pat. No. 8,728,981) is a commercially available phagemid library that uses Fab was displayed on the phage surface using the Fab technology (Lohning et al., WO2001 / 05950). To further improve affinity, species cross-reactivity and biological activity, the previously used Diversification of technology generation Maturation module (van den Brulle et al., 2008) simultaneously optimizes CD3-mAb GP In order to select CD3-mAbs with improved affinity GP Derivatives were used, and three rounds of maturation panning were performed on phages from the mature library. The panning stringency was increased by reducing the CD3 antigen concentration or the number of cells expressing CD3 in each round of panning (Low et al., 1996). In addition to reducing the antigen, dissociation rate selection (Hawkins et al., 1992) was performed, using excess non-biotinylated CD3ε antigen as a competitor to further increase the selection stringency. All strategies were combined with extended washing steps.

[0408] Example 1.1: SET affinity screening after affinity maturation

[0409] To generate crude bacterial lysates (BEL extracts) containing Fab for primary affinity screening, microtiter plates pre-filled with growth medium (2xYT containing chloramphenicol, IPTG, and low glucose) were inoculated with bacterial glycerol stocks containing Fab. The plates were incubated at 37°C to grow the bacteria and shaken overnight at 22°C to express the Fab. The next day, the expression culture was lysed by adding BEL buffer containing borate buffer, EDTA, and lysozyme. The volume was adjusted according to the selected plate format and application.

[0410] SET (solution equilibrium titration) screening (Della Ducata et al., 2015) was performed in principle as described by Haenel and colleagues (Haenel et al., 2005). A constant amount of BEL extract containing diluted Fab was equilibrated overnight with different concentrations of CD3ε antigen (hCD3e(22-118)_FLAG_chLys_avi (SEQ ID NO:43)). The mixture was then transferred to an MSD plate previously coated with antigen and, after incubation and washing, the appropriate MSD-Sulfo-tag labeled detection antibody was added. Subsequently, the concentration of unbound Fab was quantified by ECL detection using a Sector Imager 6000 (Meso Scale Discovery│Gaithersburg│MD│USA). The results were processed using XLfit (IDBS) software, applying the corresponding fitting model as described above to estimate affinity and thus identify clones that improved the most after maturation.

[0411] Approximately 1000 clones obtained from the third round of panning were screened for affinity, of which 189 clones showed affinity for the recombinant human CD3ε antigen SET K D Estimated value ≤40nM, VH or VL sequencing was performed as needed. Sequencing results identified 101 sequence-unique HCDR1+2 affinity-matured derivatives, but only 15 sequence-unique LCDR3 affinity-matured CD3-mAbs GP derivative.

[0412] Example 1.2: Conversion and generation of a bispecific 2+1 Fab2-Fc-scFv antibody format

[0413] In order to determine whether the sequence-specific affinity-optimized CD3-specific antibodies in Example 1.1 are suitable for use in a bispecific antibody format, CD3-MAB GP , 48x sequence-unique HCDR1-3 and 3x sequence-unique LCDR3 derivatives (SET K for human CD3ε D Estimated value ≤ 10 nM) of VH and VL were converted into a bispecific 2+1 Fab2-Fc-scFv antibody format, such as Figure 1As shown in A. This bispecific antibody format is constructed from an aglycosylated human IgG1 backbone and contains an additional scFv fragment, the N-terminus of the scFv VL domain is fused to the C-terminus of an IgG heavy chain via a peptide linker. In order to promote heterodimerization of two different heavy chains, knob-into-hole mutations are introduced into the two CH3-Fc domains. In this embodiment, both Fab arms of the IgG backbone bind to the tumor target HER2, and the additional scFv contains the variable domain of the CD3-specific antibody disclosed in the present invention. For HER2 binding, the encoding "trastuzumab" described in Baselga et al. 1998, Cancer Res 58(13):2825-2831 is used. The nucleotide sequences of the VH and VL domains of trastuzumab and its preparation method are described in US 5,821,337. Table 10 lists the CD3-MAB prepared according to Example 1.2 with improved affinity. opt_VL An exemplary bispecific antibody BissIg_08_#1 having a VL domain of SEQ ID NO: 25 and SEQ ID NO: 20 or a CD3-MAB carrying an affinity-improved opt_VH#1 Summary of the polypeptide sequences of the exemplary bispecific antibody BissIg_08_#2 containing the VH domains of SEQ ID NO: 14 and SEQ ID NO: 26.

[0414] All nucleic acid sequences or desired gene fragments are either generated by PCR using appropriate templates or are gene synthesized by internal or external suppliers as linear DNA fragments with appropriate flanking regions (e.g., suitable restriction endonuclease recognition sites, linker sequences). Nucleic acid sequences or gene fragments flanked by single restriction endonuclease cleavage sites are cloned into corresponding mammalian expression vectors using standard molecular biology methods. When intended for mammalian expression vectors, all constructs are designed with a 5'-end DNA sequence encoding a leader peptide that targets proteins for secretion in eukaryotic cells. The DNA sequence of the subcloned gene fragments is confirmed by double-stranded sequencing using DNA. Eukaryotic HEK293-6E cells are transfected with mammalian expression vector DNA encoding all components of the heavy and light chains of the bispecific antibody to produce 2:1:1 heterodimeric bispecific antibodies. Cell culture supernatants were harvested 7 days after transfection and Protein A affinity chromatography (MabSelect SURE│GE Healthcare) was performed using a liquid handling station. The sample was retained in a neutralization elution buffer (NaPS: 137 mM sodium phosphate, 81 mM NaCl, pH 7). The sample was sterile filtered (0.2 μm pore size). Protein concentration was determined by UV spectrophotometry, and antibody purity was analyzed using CE-SDS (LabChip GXII│Perkin Elmer│USA) under denaturing and reducing conditions. HP-SEC was performed to analyze the bispecific antibody preparation in the native state.

[0415] In summary, 41 / 51 bispecific antibodies were produced with a monomer content of >85% as determined by analytical size exclusion chromatography, with acceptable quality and yield. Table 16 summarizes the monomer content of the 7 bispecific antibody preparations produced, which contained the progenitor CD3 antibody CD3-MAB GP or the variable domains of the 6 preferred affinity-optimized CD3 antibodies as described above, including CD3-MABopt_VL and CD3-MABopt_VH#1.

[0416] Functional characterization of an affinity-optimized CD3-specific antibody in a bispecific 2+1 Fab2-Fc-scFv antibody format

[0417] All bispecific antibodies generated in Example 1.2 were tested in in vitro assays including:

[0418] Affinity determination by surface plasmon resonance (SPR)

[0419] Binding to human T cells and Jurkat cells that endogenously express CD3, and J.RT-T3.5 cells that do not express CD3

[0420] Functional NFAT reporter gene assay using cancer cell line SKBR3.

[0421] Functional cytotoxicity assay was performed on SKBR3 cells.

[0422] Example 1.3: Determination of K by Antibody Capture Device D

[0423] The interaction between human CD3ε and 41 bispecific Fab2-Fc-scFv antibodies generated in Example 1.2 was kinetically characterized in an antibody capture format, where the antigen was applied as an analyte in solution. A high-capacity capture surface was prepared by loading the biotinylated MabSelect SuRe ligand (non-biotinylated ligand: GE Healthcare, 28-4018-60) onto multiple streptavidin sensors (fortébio, part 18-5021). Each cycle of the kinetic experiment consisted of a capture step (of one ligand on multiple sensors used in parallel) followed by an analyte binding step (binding phase, different analyte concentrations and assay buffer, i.e., antigen concentration of 0 for blank subtraction). After binding, the dissociation of the bound antigen was monitored (sensor exposure to assay buffer). At the end of each cycle, the bound ligand and / or ligand-antigen complex was removed from the sensor surface by 2 consecutive regeneration steps à 20 s using 10 mM glycine / HCl pH 1.5 (GE Healthcare, BR 100354), while maintaining the integrity of the capture surface. The signal recorded on the sensor for the captured ligand (not exposed to antigen during binding but to the assay buffer) was subtracted from the sensorgram with a non-zero antigen concentration to correct for potential dissociation of the captured ligand, for example. Binding and dissociation were recorded for 300 s at an orbital shaking speed of 1000 rpm. DPBS (GIBCO, Ca-free) supplemented with 0.05% (v / v) polysorbate 20 (Merck, 8.22184.0500) and 0.1% (w / v) bovine serum albumin (Sigma, A7906) was used. 2+ , Mg-free 2+ ; Thermo Fisher Cat. No. 14190) was used as the assay buffer. The capture level of the ligand was adjusted to approximately 2 nm to reach a saturation level of human CD3e analyte, Rmax, of approximately 0.2 nm. During the kinetic experiments, seven different analyte concentrations were used for analysis (hCD3e (22-118)_F-chLys_avi (SEQ ID NO: 43); molar concentrations of 15.6–1000 nM were applied in a 2-fold serial dilution series). The sensorgrams were evaluated using the data analysis software v 10 (Octet / fortébio). All sensorgrams were fitted to a 1:1 binding model to determine k on and k off rate constants, and then use them to calculate KD For kinetic profiles that deviate from the expected 1:1 binding, the sensorgrams are evaluated using the best approximation of monovalent kinetics and the results are labeled “heterogeneous binding.” These results are considered less accurate than kinetic profiles that exactly follow the expected monovalent binding kinetics but are considered to be K D A good approximation of .

[0424] Overall, the determined monovalent affinities of all 41 tested affinity-optimized CD3-specific antibodies for human CD3e antigen ranged from 39 nM to 120 nM, whereas the progenitor antibody CD3-MAB GP When tested in the same bispecific antibody format, K D Table 16 summarizes the results of the studies on CD3-MAB. GP The results of kinetic studies determined for 6 preferred affinity-optimized CD3 antibodies according to the present disclosure, including CD3-MABopt_VL (BissIg_08_#1) and CD3-MABopt_VH#1 (BissIg_08_#2).

[0425] Example 1.4: Cell Binding

[0426] The 41 bispecific Fab2-Fc-scFv antibodies (including the affinity-improved CD3-specific antibodies) generated in Example 1.2 were tested for their ability to bind to CD3-positive human T cells and the CD3-negative cell line J.RT3-T3.5.

[0427] To isolate and purify human T cells, human whole blood from healthy donors was collected in S-Monovette containers (Sarstedt) containing Li-Heparin. The blood was transferred to a 50 ml conical tube and mixed with an equal volume of PBS containing 2% fetal bovine serum (Sigma, #F7524) and 2 mM EDTA. The diluted blood was transferred to a SepMate-50 tube (StemCell Technologies, #86450) containing 15 ml of Biocoll solution (Biochrom, #L6115) and centrifuged at 1200 x g for 10 minutes. The supernatant was transferred to a 50 ml conical tube, diluted to 45 ml with PBS, and centrifuged at 300 x g for 8 minutes. The supernatant was discarded, the cell pellet was resuspended with 1 ml PBS, and the cells were counted using a Neubauer chamber. EasySep was used according to the supplier's instructions. TMT cells were isolated and purified using the Human T Cell Isolation Kit (StemCell Technologies). Purity of CD3+ T cells was assessed by flow cytometry using an anti-human CD3 PE-conjugated antibody (Biolegend #12-0037-42). Jurkat and J.RT3-T3.5. cells were resuspended and counted with Superblock (ThermoScientific, #37515) and blocked on ice for 1 hour. Blocked cells were resuspended with serially diluted bispecific antibodies in Superblock (starting and ending concentrations: 500nM–0.69nM / 0.23nM; 1:3 dilution series) and incubated on ice for 1 hour. Cells were washed twice with D-PBS (Gibco) containing 3% fetal bovine serum (Sigma, #F7524). Bound bispecific antibodies were detected using AlexaFluor 647 labeled goat anti-human IgG, F(ab')2 fragment specific (Jackson Immuno Research Cat#109-606-097). Antibody staining was measured using a FACS Array (Beckton Dickinson) or IntelliCyt iQue flow cytometer and analyzed in FlowJo or ForeCyt (IntelliCyt) software, respectively. EC was calculated using 4-parameter nonlinear regression analysis in Prism software (GraphPad Software Inc.). 50 value.

[0428] Table 16 summarizes the results of the present invention for the CD3-MAB-containing GP The results of cell binding studies of the bispecific antibody assay according to Example 1.2 of the variable domains of the 6 preferred affinity-optimized CD3 antibodies, including CD3-MABopt_VL (BissIg_08_#1) and CD3-MABopt_VH#1 (BissIg_08_#2). Cell binding was shown as a signal above background at a selected antibody concentration of 167 nM. GP In comparison, the affinity-improved CD3-specific antibodies showed significantly stronger signal intensities for human T cells. In addition, no or only very weak binding was observed for the CD3-negative cell line J.RT3-T3.5. (data not shown).

[0429] Example 1.5 Jurkat NFAT reporter gene cell assay

[0430] To evaluate the functional activity of the bispecific Fab2-Fc-scFv antibodies according to Example 1.2, Jurkat cells (ATCC #TIB-152) transiently transfected with the NFAT reporter gene construct were used as surrogate effector cells. As target cells, HER2-positive human adenocarcinoma SKBR-3 ( HTB-30 TM ) cell lines. The following growth media were used to maintain the cell lines: (a) Jurkat: RPMI-1640 + L-glutamine (Thermo Fisher, #21875-034), supplemented with 10% FCS (Sigma, #F7524); (b) SKBR-3: McCoys 5a (Gibco, #26600), supplemented with 10% FCS (Sigma #F7524). SKBR-3 cells were diluted to a density of 4E+05 cells / ml in growth media. 100 μl of cell suspension equivalent to 40,000 cells was plated into each well of a tissue culture treated 96-well plate (Corning, #3917) and incubated overnight in a humidified incubator at 37°C and 5% CO2. Jurkat cells were resuspended in growth media at a concentration of 2.5E+05 cells / ml. The transfection components pGL4.30[luc2P / NFAT-RE / Hygro] reporter gene vector (Promega #9PIE848), OptiMEM-I medium (Life Technologies, #31985-047), and TransIT-LT1 transfection reagent (Mirus, #MIR2304) were incubated at room temperature for 15 minutes, then added to the Jurkat cell suspension and incubated in a humidified incubator at 37°C and 5% CO2 for 17 hours. Jurkat cells were harvested and resuspended in growth medium at a concentration of 1.2E+06 / ml. The medium was removed from the coated target cells and replaced with 50μl Jurkat cell suspension, equivalent to 60,000 cells per well. The bispecific antibodies were serially diluted in Jurkat growth medium. 50μl of antibody dilution was added to each well, with a final concentration range of 10nM to 0.01nM (4-step dilution). The test plate was incubated in a humidified incubator at 37°C and 5% CO2 for 5 hours. Reconstitute Bright-Glo according to the manufacturer's instructions. TM Reagents (Promega, #E2620). The detection plate and reagents were equilibrated at room temperature. 100 μl Bright-Glo TM Reagents were added to each well of the assay plate and mixed. Luminescence was measured using an Infinite M1000 Pro plate reader (Tecan).

[0431] Table 16 summarizes the results of the present invention for the CD3-MAB-containing GP Reporter gene assay results of bispecific antibody assays of variable domains of 6 preferred affinity-optimized CD3-specific antibodies, including CD3-MABopt_VL (BissIg_08_#1) and CD3-MABopt_VH#1 (BissIg_08_#2). Results are shown as signals above background at a bispecific antibody concentration of 1 nM. GP Compared to bispecific antibodies containing variable domains of 50-fold less than 100 nt (which showed hardly any activity), bispecific antibodies comprising affinity-optimized CD3-specific antibodies showed significantly stronger activation of the reporter gene system in Jurkat cells.

[0432] Example 1.6: Cytotoxicity assay using bispecific antibodies.

[0433] The ability of 41 bispecific Fab2-Fc-scFv antibodies according to Example 1.2 (including affinity-optimized CD3-specific antibodies) to mediate T cell-dependent killing of HER2-expressing SKBR3 cells or HER2-negative MDA-MB468 cells was tested. PBMCs were prepared as described in Example 1.4. 5,000 SKBR3 or MDA-MB468 cells were suspended in culture medium (SKBR3: McCoy's 5A medium (Gibco, #26600), 10% FCS (Sigma, #F7524); MDA-MB468: DMEM (Gibco, #10938), GlutaMax (Gibco, #35050), 10% FCS, 1x sodium pyruvate (Gibco, #11360-039)), seeded in a black 96-well assay plate (Corning, #3340), and incubated overnight at 37°C and 5% CO2. CellToxGreen dye (Promega, #G8731), serially diluted bispecific antibody constructs (final concentration: 5nM–100pM), and 100,000 purified PBMCs (all diluted in assay medium containing RPMI 1640 w / o phenol red (Gibco, #32404-014), GlutaMax, and 10% fetal bovine serum) were added to the cells and incubated for 48 hours at 37°C and 5% CO2. The incorporated CellToxGreen fluorescence was measured at 485nm excitation and 535nm emission using a Tecan Infinite F500 instrument, and cytotoxic activity was assessed after 72 hours. EC was calculated using 4-parameter nonlinear regression analysis in Prism software (GraphPad Software Inc.). 50 value.

[0434] Overall, only 24 of the tested bispecific antibodies comprising affinity-optimized CD3-specific variable domains of Example 1.2 mediated T cell killing of SKBR3 cells. GP No killing was observed for the bispecific antibodies containing the variable domains. Table 16 summarizes the killing of the antibodies containing the CD3-MAB according to the present disclosure. GP Results of T cell redirected killing of SKBR3 cells by bispecific antibodies of variable domains of 6 preferred affinity-optimized CD3 antibodies (IC 50 concentrations), including those for CD3-MABopt_VL(BissIg_08_#1) and CD3-MABopt_VH#1(BissIg_08_#2).

[0435] Example 1.7: ELISA binding

[0436] The binding ability of the bispecific Fab2-Fc-scFv antibodies according to Example 1.2 to recombinant human and cynomolgus CD3ε antigens was tested in ELISA. 5nM recombinant human CD3e (22-49) -Fc2 (K105-K330) (SEQ ID NO: 41) or 1nM recombinant cynomolgus CD3e (22-49) -Fc2 (K105-K330) (SEQ ID NO: 42) was coated on Maxisorp plates (Nunc, #460518). The coated plates were blocked with 5% skim milk powder in PBS. The antibodies were serially diluted in PBS containing 0.5% skim milk powder and 0.5% Tween-20. Bound antibodies were detected using an alkaline phosphatase-coupled detection antibody against human F(ab')2 fragments (Jackson Immuno Research, #109-055-097). EC was calculated using 4-parameter nonlinear regression analysis in Prism software (GraphPad Software Inc.). 50 value.

[0437] Table 15 summarizes the results of the present disclosure for the progenitor antibody CD3-MAB GP ELISA EC of bispecific antibody assay with variable domains of 6 preferred affinity-optimized CD3 antibodies, including CD3-MABopt_VL (BissIg_08_#1) and CD3-MABopt_VH#1 (BissIg_08_#2) 50 The results showed that compared with the progenitor antibody CD3-mAb GP In comparison, affinity-optimized CD3-specific antibodies showed 10- to 20-fold improvement in binding to human and cynomolgus monkey CD3ε antigens.

[0438] Table 15: ELISA binding of the affinity-improved CD3-specific antibodies of the present disclosure to recombinant human or cynomolgus CD3 epsilon antigen when tested in the bispecific antibody format Fab2-Fc-scFv of Example 1.

[0439]

[0440] na: Not applicable

[0441] Summary of functional properties of affinity-improved antibodies

[0442] Progenitor antibody CD3-mAb GP Affinity maturation of 5 CD3-mAbs led to the identification of GP Affinity optimized HCDR1-2 variants and 1 affinity optimized LCDR3 variant, which have preferred properties and are suitable for use in bispecific antibody formats. Table 16 summarizes the favorable functional and biophysical properties of these antibodies compared to the ancestral antibodies when tested in the bispecific antibody format of Example 1.

[0443] Table 16: Summary of functional and biophysical properties of affinity-optimized CD3-specific antibodies according to the present disclosure.

[0444]

[0445] na: Not applicable

[0446] Example 2: Further optimization of affinity-improved CD3-specific antibodies - cross-cloning of affinity-optimized variable domain and converted into another bispecific antibody format

[0447] To further improve the functional properties of the previously identified affinity-optimized CD3-specific antibodies, five cross-clones were generated by combining the VHs of CD3-MABopt_VH#1 (SEQ ID NO: 14), CD3-MABopt_VH#2, CD3-MABopt_VH#3, CD3-MABopt_VH#4, and CD3-MABopt_VH#5 with the VL of CD3-MABopt_VL (SEQ ID NO: 20).

[0448] Subsequently, the affinity-improved antibodies CD3-MABopt_VH#1, CD3-MABopt_VH#2, CD3-MABopt_VH#3, CD3-MABopt_VH#4, CD3-MABopt_VH#5, and CD3-MABopt_VL, as well as the five cross-clones generated therefrom, were converted into a bispecific 1+1 antibody format, e.g. Figure 1B. The bispecific antibody format of Example 2 has the typical Y-shape of a conventional IgG molecule, in which one Fab arm binds to the tumor target (HER2) and the other Fab arm binds to CD3. For HER2 binding, "trastuzumab" described in Baselga et al., 1998, Cancer Res 58(13):2825-2831 was used. The VH and VL domains of trastuzumab are SEQ ID NO: 28 and SEQ ID NO: 29, respectively. Trastuzumab and methods for its preparation are described in US Pat. No. 5,821,337.

[0449] Bispecific 1+1 antibodies were generated in vitro by 2-MEA-induced Fab-arm exchange, as described in WO2011147986, WO2011131746 and WO2013060867 and Labrijn et al. (Labrijn et al., PNAS 2013, 110:5145-50; Gramer et al., MAbs 2013, 5:962-973). In order to be able to produce bispecific antibodies by this method, two source IgG1 molecules carrying CH3 domain mutations were generated: one source IgG1 antibody had a F405L mutation (i.e., a CD3-specific antibody) and the other source IgG1 antibody had a K409R mutation (e.g., an anti-HER2 antibody). In addition to these mutations, the source IgG1 molecule also included substitutions that render the Fc region unable to interact with the IgG Fc receptor (Fcγ receptor) and complement: L234A, L235E, G237A, A330S, and P331S ("AEASS").

[0450] Table 11 lists a summary of the polypeptide sequences that formed two exemplary generated source IgG1 molecules, which are specific for HER2 (IgG#1: SEQ ID NOs: 53 and 51) or CD3 (IgGopt_cc: (SEQ ID NOs: 54 and 55), respectively, and were prepared according to Example 2. The CD3-specific IgG contained the VH and VL of the cross-cloned CD3-MABopt-cc (SEQ ID NOs: 14 and 20, respectively). Table 12 lists a summary of the polypeptide sequences (SEQ ID NOs: 53, 51, 54, 55) that formed the resulting (after Fab arm exchange) bispecific 1+1 antibody BissIg_18_opt_cc#.

[0451] For routine production of source IgG1 molecules, eukaryotic HEK293-6E cells were transfected with mammalian expression vector DNA encoding the heavy and light chains of the source IgG molecules. Cell culture supernatants were harvested on the 3rd or 6th day after transfection and subjected to standard ProteinA affinity chromatography (MabSelect SURE│GE Healthcare). The buffer was exchanged with 1x Dulbcecco's PBS (pH 7.2│Invitrogen), and the samples were sterile filtered (0.2 μm pore size). Protein concentration was determined by UV spectrophotometry, and CE-SDS (LabChip GXII│Perkin Elmer│USA) was used to analyze the purity of IgG under denaturing, reducing and non-reducing conditions. HP-SEC was performed to analyze the native IgG preparation.

[0452] To generate bispecific 1+1 antibodies by Fab arm exchange, the two source IgGs were mixed in equal amounts in PBS buffer (phosphate-buffered saline; 8.7 mM HPO4 2- , 1.8 mM H2PO 4- , 163.9mM Na+, 140.3mM Cl-, pH 7.4). 2-Mercaptoethylamine-HCl (2-MEA) was added to a final concentration of 75mM, and the reaction mixture was incubated at room temperature for 5 hours. 2-MEA was removed by exchanging the buffer with PBS using a PD-10 column to re-oxidize the interchain disulfide bonds and form a complete bispecific antibody. Protein concentration was determined by UV spectrophotometry, and CE-SDS (LabChip GXII│PerkinElmer│USA) was used to analyze the purity of the bispecific IgG preparation under denaturing, reducing and non-reducing conditions. HP-SEC was performed to analyze the bispecific IgG preparation in the native state.

[0453] Table 17-1 summarizes the quality control of mammalian produced source IgG1 molecules before controlled Fab arm exchange (FAE) for the affinity improved CD3-specific antibodies CD3-MABopt_VH#1, CD3-MABopt_VH#2, CD3-MABopt_VH#3, CD3-MABopt_VH#4, CD3-MABopt_VH#5 and CD3-MABopt_VL according to Example 1. Table 17-2 summarizes the quality control of mammalian produced source IgG1 molecules before controlled Fab arm exchange (FAE) for the affinity improved CD3-specific antibodies CD3-MABopt_VH#1, CD3-MABopt_VH#2, CD3-MABopt_VH#3, CD3-MABopt_VH#4, CD3-MABopt_VH#5 and CD3-MABopt_VL according to Example 2. opt_cc 、CD3-MAB opt_cc#2 、CD3-MAB opt_cc#3 、CD3-MAB opt_cc#4 and CD3-mAb opt_cc#5Quality control of mammalian-derived IgG1 molecules.

[0454] Overall, IgG comprising cross-cloned CD3-specific antibody variable domains showed lower IgG preparation monomer content compared to IgG comprising only affinity-improved CD3-specific antibody variable domains.

[0455] Table 17-1: Quality control of source IgG containing affinity-optimized CD3-specific antibodies produced before Fab arm exchange

[0456]

[0457] na: Not applicable

[0458] Table 17-2: Quality control of source IgG containing CD3-specific cross-clones generated before Fab arm exchange

[0459]

[0460] The quality control of bispecific IgG preparations containing cross-cloned CD3-specific binding domains after controlled Fab-arm exchange (FAE) is summarized in Table 18. Overall, the bispecific antibody preparations showed higher monomer content compared to the corresponding source monospecific IgG preparations.

[0461] Table 18: Quality control of bispecific antibodies comprising cross-cloned CD3-specific binding domains generated after Fab arm exchange.

[0462]

[0463] Example 2.1: Determination of K by Antibody Capture Device D

[0464] Affinity determination was performed by measuring kinetic rate constants on an Octet HTX (ForteBIO, Sartorius AG) instrument. The bispecific antibody formulation of Example 2 was diluted with an assay buffer (DPBS (GIBCO, Ca2+) supplemented with 0.05% (v / v) polysorbate 20 (Merck, 8.22184.0500) and 0.1% (w / v) bovine serum albumin (Sigma, A7906)). 2+ , Mg-free 2+;Thermo Fisher Cat.No.14190) was diluted and captured on the IgG-specific BLI sensor at a load level of about 2nm. For analysis, the human CD3ε antigen hCD3e(22-118)_F-chLys_avi-biotin (SEQID NO:43) was diluted with assay buffer to a concentration range of 7.8nM to 500nM (continuous 1:2 dilution). A blank sample with assay buffer was included for reference, i.e., to correct the dissociation of the capture antibody. The binding phase was recorded for 180s, followed by a 300s dissociation phase. After each cycle, the biosensor was regenerated twice with 10mM glycine HCl pH 1.7 to remove the bound ligand / antibody complex while maintaining the integrity of the capture surface. Between the regeneration steps, the biosensor was washed with assay buffer for 20 seconds. The sensor graph was evaluated with data analysis software v 10 (Octet / fortébio). All sensor graphs were fitted to a 1:1 binding model to determine k on and k off The rate constant used to calculate K D For kinetic curves that deviate from the expected 1:1 binding, the sensorgrams are evaluated using the best approximation to monovalent kinetics and the results are labeled “heterogeneous binding.” These results are considered less accurate than kinetic curves that exactly follow the expected monovalent binding kinetics but are considered to be K D A good approximation of .

[0465] Table 19 summarizes the K values ​​of bispecific antibodies comprising affinity optimized or cross-cloned CD3-specific binding domains according to the present disclosure. D The optimized or cross-cloned CD3-specific antibodies recognized the recombinant human CD3ε antigen, K D The values ​​were in the low single-digit nanomolar range, except for the HCDR1-2 mature antibody CD3-MABopt_VH#1 (SEQ ID NO: 14 and SEQ ID NO: 26) and the LCDR3 mature antibody CD3-MABopt_VL (SEQ ID NO: 25 and SEQ ID NO: 20). These two antibodies showed heterogeneous binding to CD3e in the low double-digit nanomolar range. Surprisingly, it was found that the cross-clone CD3-MABopt_cc (SEQ ID NO 14 and SEQ ID NO: 20) generated by the VH of CD3-MABopt_VH#1 and the VL of CD3-MABopt_VL construction showed an approximately 20- to 30-fold increase in binding affinity to CD3e compared to its source antibodies.

[0466] Table 19: K of bispecific 1+1 antibodies specific for CD3 and HER2 according to Example 2 against human CD3ε D value.

[0467]

[0468] Example 2.2: Cell Binding

[0469] The binding ability of the bispecific antibodies (CD3-specific antibodies comprising affinity-improved or cross-cloned antibodies) according to Example 2 of the present disclosure to Jurkat (CD3+) and J.RT3-T3.5 (CD3-) cells was tested. The target cells were mixed with bispecific antibodies serially diluted (final concentration: 0.1nM–200nM) in D-PBS (Gibco) containing 3% fetal bovine serum (Sigma, #F7524) and incubated on ice for 1 hour. The cells were washed twice in D-PBS (Gibco) containing 3% fetal bovine serum (Sigma, #F7524) and 0.02% sodium sulfate. The bispecific antibodies were detected using goat anti-human IgG, F(ab')2 fragment specificity (Jackson Immuno Research Cat#109-606-097) labeled with AlexaFluor 647. Antibody staining was measured using a FACS Array (Beckton Dickinson) or IntelliCyt iQue flow cytometer and analyzed in FlowJo or ForeCyt (IntelliCyt) software, respectively. EC was calculated using 4-parameter nonlinear regression analysis in Prism software (GraphPad Software Inc.). 50 value.

[0470] Table 20 and Figure 3 Summarize the cell binding of the test bispecific antibody preparations according to the CD3 specific antibody variable domains comprising affinity maturation or cross-cloning of the present disclosure.In general, compared with the counterparts of affinity maturation only, CD3 specific cross-cloning shows stronger binding with Jurkat cells.Specifically, cross-clone CD3-MABopt_cc (SEQ ID NO:14 and SEQ ID NO:20) shows the strongest binding with Jurkat cells.The binding with CD3 negative cell line J.RT3-T3.5. is observable for two kinds of CD3 specific antibodies (CD3-MABopt_VH#2 and CD3-MABopt_VH#5) and two kinds of cross-clone counterparts (CD3-MABopt_cc#2 and CD3-CD3-MABopt_cc#5) with improved affinity.

[0471] Table 20: Table 20: Cellular binding (EC 50 value).

[0472]

[0473] Example 2.3 Jurkat NFAT reporter gene cell assay

[0474] To evaluate the functional activity of the bispecific antibody of Example 2, Jurkat cells (ATCC #TIB-152) transiently transfected with NFAT reporter gene construct were used as surrogate effector cells. As HER2-positive target tumor cell line, SKOV-3 ( HTB-77 TM ) and MCF-7( HTB-22 TM). The assay was performed essentially as described in Example 1.5. The following growth media was used to maintain the cell lines: Jurkat: RPMI-1640 + L-glutamine (ThermoFisher, #21875-034), supplemented with 10% FCS (Sigma, #F7524); SKOV-3: McCoys 5a (Gibco, #26600), supplemented with 10% FCS (Sigma #F7524) MCF-7: DMEM (Gibco #10938), supplemented with +10% FCS (Sigma #F7524) + 1x Glutamax (Gibco #35050-061) + 1x Sodium Pyruvate (Gibco #11360-039). SKOV-3 and MCF-7 cells were diluted to a density of 4E+05 cells / ml in growth media. 100 μl of cell suspension equivalent to 40,000 cells was inoculated into each well of a tissue culture treated 96-well plate (Corning, #3917) and incubated overnight in a humidified incubator at 37°C and 5% CO2. Jurkat cells were suspended in growth medium at a concentration of 2.5E+05 cells / ml. The transfection components pGL4.30[luc2P / NFAT-RE / Hygro] reporter gene vector (Promega #9PIE848), OptiMEM-I medium (Life Technologies, #31985-047) and TransIT-LT1 transfection reagent (Mirus, #MIR2304) were incubated at room temperature for 15 minutes and then added to the Jurkat cell suspension and incubated in a humidified incubator at 37°C and 5% CO2 for 17 hours. Jurkat cells were harvested and resuspended in growth medium at a concentration of 1.2E+06 / ml. Remove medium from coated target cells and replace with 50 μl Jurkat cell suspension, equivalent to 60,000 cells per well. Bispecific antibodies were serially diluted in Jurkat growth medium. 50 μl of antibody dilution was added to each well to give a final concentration range of 50 nM to 0.01 nM (4-step dilution). The assay plate was incubated in a humidified incubator at 37°C and 5% CO2 for 5 hours. Bright-Glo was reconstituted according to the manufacturer's instructions. TM Reagents (Promega, #E2620). The assay plate and reagents were equilibrated at room temperature. 100 μl Bright-Glo was added to each well of the assay plate. TM The reagents were added and mixed. Luminescence was measured using an Infinite M1000Pro plate reader (Tecan).

[0475] Table 21 summarizes the activation of the Jurkat cell / NFAT reporter system mediated by the bispecific antibodies of the present disclosure. Again, the bispecific antibody BissIg_18_opt_cc# comprising the cross-cloned antibody CD3-MABopt_cc (SEQ ID NO: 14 and SEQ ID NO: 20) showed the strongest activation of the Jurkat cell / NFAT reporter system in the presence of SKOV-3 and MCF-7 cells, EC 50 The value is less than 0.2nM.

[0476] Table 21: Reporter gene assay using bispecific antibodies specific for HER2 and CD3 according to Example 2 of the present disclosure (comprising affinity matured or cross-cloned CD3-specific binding domains).

[0477]

[0478] ">" = Incomplete titration / poor fit

[0479] Example 2.4: Cytotoxicity assay using bispecific antibodies.

[0480] The ability of the bispecific antibody according to Example 2 to mediate T cell-dependent killing of HER2-expressing tumor cell lines SKBR3, MCF-7, and HER2-negative cell line MDA-MB-468 was tested. The assay was performed as described in Example 1.6. As effector cells, human PBMC (for SKBR3) cells or purified human T cells (for MCF-7 cells) were used. The preparation and purification of human PBMC and human T cells were performed as described in Example 1.4. 5000 SKBR-3, MDA-MB-468 or MCF-7 cells were seeded in a black 96-well assay plate (Corning, #3340) and incubated overnight at 37°C and 5% CO2. CellToxGreen dye (Promega, #G8731), serially diluted bispecific antibody constructs and 100.000 purified PBMCs (for SKBR-3 cells) (target cell / effector cell ratio of 1:20) or 50.000 purified T cells (for MCF-7 cells) (target cell / effector cell ratio of 1:10), all diluted in assay medium, added to the cells and incubated for 72 hours at 37°C and 5% CO2. After 72 hours, cytotoxic activity was assessed by measuring the incorporated CellToxGreen fluorescence at 485 nm excitation and 535 nm emission using a Tecan Infinite F500 device. EC was calculated using 4-parameter nonlinear regression analysis in Prism software (GraphPad Software Inc.). 50 value.

[0481] Table 22 and Figure 4 (One donor) summarizes the T cell redirection killing of cancer cell lines mediated by the bispecific antibodies of the present disclosure. The bispecific antibodies containing cross-cloned CD3-specific antibodies clearly showed excellent killing of both SKBR3 cells and MCF-7 cells. Among them, the bispecific antibody BissIg_18_opt_cc# containing the cross-cloned antibody CD3-MABopt_cc (SEQ ID NO: 14 and SEQ ID NO: 20) showed the best killing activity against two cancer cell lines. At higher test antibody concentrations, the cross-clone CD3-MABopt_cc#4 had weak cell killing against the HER2-negative cell line MDA-MB-468 (data not shown).

[0482] Table 22: T cell-mediated killing assays using bispecific antibodies specific for HER2 and CD3 according to Example 2 of the present disclosure (including affinity matured or cross-cloned CD3-specific antibodies).

[0483]

[0484] *Poor fit; nt = not tested

[0485] Example 2.5: Activation of T cells in the absence of target cancer cells (high-density PBMC assay)

[0486] The bispecific antibodies of Example 2 were tested for their ability to activate human T cells from human blood samples from three different donors in the absence of target cancer cells. The assay was performed under high PBMC density pre-culture conditions, such as and colleagues suggested ( et al. BLOOD, December 22, 2011, Vol. 118, No. 26, pp. 6772-6781). The preparation and purification of human PBMCs were as described previously (see Example 1.4). T cells were resuspended in RPMI 1640 medium (Gibco, #31870-025) supplemented with GlutaMax (Gibco, #35050-038), non-essential amino acids (Gibco, #11140-035), HEPES buffer solution (Gibco #15630-056), sodium pyruvate (Gibco, #11360-039), β-mercaptoethanol, penicillin / streptomycin (Gibco #15140-122) and human serum (Sigma, #H4522) at a density of 1E+07 cells / mL and incubated at 37°C and 5% CO2 for 48 hours. After high-density pre-incubation, 200,000 PBMCs in the culture medium were mixed with an equal volume of serially diluted antibodies (final concentrations: 1000nM, 200nM, and 40nM) and incubated at 37°C and 5% CO2 for 24 hours. As a positive control, a commercially available murine IgG antibody OKT3 was used. T cell activation was assessed by evaluating the upregulation of CD69 expression on CD3-positive lymphocytes. To this end, PBMCs were stained with CD3 and CD69 antibodies (Biolegend, #300434, #12003742, #310910) bound to BV / PE and APC, respectively. Antibody staining was measured using a NovoCyte 3000 flow cytometer (AceaBiosciences, Inc.) and analyzed using FlowJo software.

[0487] Figure 5 Human CD8 obtained from 3 donors + Averaged exemplary results of T cell activation experiments with T cells. As expected, a strong upregulation of CD69 expression was observed in the positive murine control IgG OKT-3. Donor-dependent CD8 + T cell activation. Among them, in the absence of target cancer cell lines, the bispecific antibody including CD3-MABopt_VH#1 (SEQ ID NO: 14 and SEQ ID NO: 26) or its cross-cloned counterpart CD3-MABopt_cc (SEQ ID NO: 14 and SEQ ID NO: 20) showed the lowest level of human T cell activation.

[0488] Example 2.6: Summary of affinity-improved and cross-cloned CD3-specific antibodies

[0489] The cross-clone CD3-MABopt_cc (SEQ ID NO: 14 and SEQ ID NO: 20) with strongly improved affinity was identified as the progenitor antibody CD3-MAB derived from the affinity maturation activity GP The most effective and safest CD3-specific antibody.

[0490] When tested in the bispecific antibody format of Example 2, CD3-MABopt_cc showed good binding to human and cynomolgus CD3 and mediated excellent cytotoxic activity on low-, medium- and high-HER2-expressing cancer cell lines, did not kill HER2-negative cancer cell lines, and had only low levels of T cell activation in the absence of target cells.

[0491] Example 3: Conversion of the optimized CD3-specific antibody CD3-MABopt-cc into an improved 2+1 Fab2-Fv-Fc antibody body form

[0492] Example 3.1: Preparation, production and characterization of linker-optimized trivalent bispecific antibodies.

[0493] Bispecific Fab2-Fv-Fc antibodies are generated in vitro using bispecific antibody platform technology, as described in WO 2020 / 115115, which is incorporated herein in its entirety. This bispecific antibody format is constructed from an aglycosylated monoclonal human IgG1 antibody backbone that includes an additional antibody Fv fragment inserted between the Fc region and the two Fab arms of a conventional human IgG1 molecule. Figure 2 The basic structure of such bispecific antibodies is provided. The advantage of such a format is that it can bind to target cell surface antigens, such as tumor-associated antigens, bivalently, but monovalently bind to CD3 expressed on T cells. This format also allows the distance between target cells and cytotoxic T cells to be very short once bridged by the bispecific antibody. This narrow immune synapse leads to effective killing of target cells by recruited cytotoxic T cells.

[0494] Example 3.2: Linker Optimization

[0495] The selection of the correct peptide linker (in terms of amino acid sequence and length) to connect the various components of the bispecific antibody format is particularly important, as these linkers determine the flexibility of the additional Fv fragment and its distance from the binding regions of the two Fab arms of the bispecific antibody. In order to further optimize the peptide linkers previously disclosed in WO 2020 / 115115, the corresponding linkers have now been extended and the sequences optimized.

[0496] N-terminal linker fused to CD3-specific Fv fragment

[0497] The C-terminus of each Fab heavy chain was fused to the N-terminus of the VH or VL of the bound CD3-specific Fv fragment using one of the following peptide linkers:

[0498] a) 9-poly-glycine-serine linker (GGS) 3: GGSGGSGGS (SEQ ID NO: 30)

[0499] b) 20 poly(G4S)4 linker: GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 31)

[0500] c) 20-poly PAPDA linker: AQPAAPAPDAHEAPAPAQGS (SEQ ID NO: 33), or

[0501] d) 20-polyPAH linker: AHPAAPAPAHPAAPAPAHGH (SEQ ID NO: 32)

[0502] C-terminal linker fused to CD3-specific Fv fragment

[0503] The fusion between the C-terminus of each of the VH and VL domains of the CD3-specific Fv fragment and the N-terminus of one of the two Fc region subunits is achieved by using one of the following peptide linkers:

[0504] i) If the VL domain of the CD3-specific Fv fragment is fused to one of the two Fc region subunits:

[0505] a) The first 5 amino acid residues of the CLλ constant domain: PKAAP (SEQ ID NO: 36)

[0506] b) 20-poly PAPDA linker: AQPAAPAPDAHEAPAPAQGS (SEQ ID NO: 33), or

[0507] c) the first 20 amino acid residues of the CL lambda constant domain: PKAAPSVTLFPPSSEELQAN (SEQ ID NO: 34), or

[0508] ii) If the VH domain of the CD3-specific Fv fragment is fused to one of the two Fc region subunits:

[0509] a) the first 6 amino acid residues of the CH1 constant domain: ASTKGP (SEQ ID NO: 37),

[0510] b) 20-poly PAPDA linker: AQPAAPAPDAHEAPAPAQGS (SEQ ID NO: 33), or

[0511] c) The first 20 amino acid residues of the CH1 constant domain: ASTKGPSVFPLAPSSKSTSG (SEQ ID NO: 35)

[0512] Table 23 lists a summary of the joint combinations tested. Figure 2 Different peptide linkers used to connect the different components of the bispecific antibody format of Example 3 are described.

[0513] Table 23: Linker combinations used to connect the VH and VL domains of the incorporated additional CD3-specific Fv fragments to the Fab arms and Fc region subunits in the bispecific Fab2-Fv-Fc antibody format.

[0514]

[0515] *As originally disclosed in WO 2020 / 115115

[0516] All C-terminal linkers are further extended at the C-terminus by a portion of the human IgG1 hinge sequence DKTHTCPPCP (SEQ ID NO: 38). The use of a truncated human IgG1 hinge sequence can further stabilize the heterodimeric molecule by forming an interchain disulfide bond between the two polypeptide chains comprising the Fab heavy chain. According to the "knobs into holes" technology, the Fc region is modified by introducing mutations in the CH3 domain of each Fc region subunit. Thus, a polypeptide comprising a mutant CH3 domain is forced to heterodimerize with another polypeptide comprising another CH3 domain designed in a complementary manner. For HER2 binding, "Trastuzumab" described by Baselga et al. in 1998 Cancer Res 58(13): 2825-2831 was used. The VH and VL domains of trastuzumab and its preparation method are described in US 5,821,337. For CD3 binding, the VH and VL of the CD3-specific cross-clone CD3-MABopt-cc of Example 2 (SEQ ID NO: 14 and SEQ ID NO: 20, respectively) were used. Table 13 lists a summary of the individual polypeptides of the bispecific trivalent Fab2-Fv-Fc antibodies produced using different linker combinations of Table 23 prepared according to Example 3.

[0517] Example 3.3: Gene synthesis and production

[0518] All nucleic acid sequences or desired gene fragments are generated by PCR using appropriate templates, or synthesized by internal or external suppliers as linear DNA fragments with appropriate flanking regions (e.g., suitable restriction enzyme recognition sites, linker sequences). Standard molecular biology methods are used to clone nucleic acid sequences or gene fragments flanked by single restriction endonuclease cleavage sites into corresponding expression vectors (e.g., mammalian expression vectors) or sequencing vectors. When used for mammalian expression vectors, all constructs are designed with 5'-end DNA sequences encoding leader peptides that target proteins for secretion in eukaryotic cells. DNA sequences of subcloned gene fragments are confirmed by double-stranded sequencing. In order to express bispecific antibodies, exponentially growing eukaryotic HEK293-6E cells are transfected with a mammalian vector expression system encoding all components of bispecific antibodies, resulting in two polypeptides containing two Fc region subunits and two polypeptides containing trastuzumab Fab light chains in a ratio of 1:1:2, respectively. Cell culture supernatants were harvested on day 6 after transfection and subjected to standard Protein A affinity chromatography (MabSelectSURE│GE Healthcare). The buffer was exchanged into 1x Dulbcecco's PBS (pH 7.2│Invitrogen), and the samples were sterile filtered (0.2 μm pore size). Protein concentration was determined by UV spectrophotometry, and the purity of the construct was analyzed under denaturing, reducing and non-reducing conditions using CE-SDS (LabChip GXII│Perkin Elmer│USA). HP-SEC was performed to analyze the bispecific antibody preparation in the native state. In addition, the molecular weight and homogeneity of the bispecific antibody were confirmed by mass spectrometry.

[0519] The monomer content and volumetric yields of the different formulations obtained for the bispecific antibodies produced are summarized in Table 24. All bispecific antibodies produced showed comparable production characteristics.

[0520] However, all bispecific antibodies using CH1- or Cλ-derived peptide linkers showed very heterogeneous mass patterns, indicating possible O-linked glycosylation with these linkers. Only the bispecific antibody BissIg_21#2 using linker combination 2 (i.e., 20 poly-glycine-serine linker (SEQ ID NO: 31) combined with 20 poly-PAPDA linker (SEQ ID NO: 33)) showed a homogeneous mass pattern with no potential signs of O-linked glycosylation.

[0521] Table 24: Quality control of mammalian produced bispecific Fab2-Fv-Fc antibodies comprising the same HER2 and CD3 binding domains but different linker combinations.

[0522]

[0523] Example 3.4: Determination of K by Antibody Capture Device D

[0524] Affinity determination was performed on an Octet HTX (FortéBIO, Sartorius AG) instrument by determining kinetic rate constants. The different bispecific antibody preparations diluted in assay buffer (D-PBS, 0.05% (v / v) PS20, 0.1% (w / v) BSA) in Example 3 were captured on an IgG-specific BLI sensor with a loading level of approximately 2 nm. For analysis, the human CD3ε antigen hCD3e(22-118)_F-chLys_avi (SEQ ID NO:43) was diluted with assay buffer to a concentration range from 1.56nM to 500nM (serial 1:3 dilutions). A blank sample containing assay buffer was included for reference, i.e., to correct for the dissociation of the capture antibody. A binding phase of 180 seconds was recorded, followed by a dissociation phase of 300 seconds. The sensor graph was fitted using Octet data analysis software 10.0 (FortéBio, Sartorius AG) to determine k on and k off rate constants (using a 1:1 binding model), which are used to calculate K D .

[0525] Table 25 summarizes the K values ​​of the bispecific antibodies of this example using different linker combinations in Table 23 for human CD3ε antigen. D Comparable CD3 binding was observed for all linker combinations tested.

[0526] Table 25: Affinity of bispecific antibodies comprising CD3-MABopt-cc variable domains but different linker combinations for human CD3ε antigen

[0527]

[0528]

[0529] *Slightly heterogeneous binding; values ​​represent best approximation to 1:1 binding

[0530] Example 3.5: Cell Binding

[0531] The binding ability of the bispecific antibodies of Example 3 containing different linker combinations of Table 23 to CD3-positive Jurkat cells and CD3-negative J.RT3-T3.5 cells was tested. Jurkat and J.RT3-T3.5. cells were resuspended, counted and blocked with washing buffer (DPBS+(Gibco) / 3% FBS(Sigma) / 0.02% sodium chloride) on ice for 1 hour. The blocked cells were resuspended in bispecific antibodies serially diluted in washing buffer (final concentration: 500nM–31pM) and incubated on ice for 1 hour. The cells were washed twice in washing buffer. Bound antibodies were detected using AlexaFluor647-labeled goat anti-human IgG, F(ab')2 fragment specific (Jackson Immuno Research Cat#109-606-097). EC was calculated using 4-parameter nonlinear regression analysis in Prism software (GraphPad Software Inc.). 50 value.

[0532] Table 26 summarizes the cell binding results (EC 50 Compared to the initially described linker combination P, bispecific antibodies specific for HER and CD3 comprising different linker combinations showed comparable binding to Jurkat cells. No binding to CD3 negative Jurkat cells (RT3-T3.5) was observed (data not shown).

[0533] Table 26: Cell Binding

[0534]

[0535] Example 3.6: Cytotoxicity assay of bispecific antibodies containing different linker combinations

[0536] The ability of bispecific antibodies comprising different linker combinations in Example 3 to induce T cell-mediated killing of HER2-expressing SKOV-3 and HER-2-negative MDA-MB468 cells was tested. Human pan T cells from two donors were prepared and purified as described previously (see Example 1.4). 5,000 HER2-expressing SKOV-3 cells were resuspended in culture medium (SKOV-3: McCoy's 5A medium (ThermoFisher, #26600), 10% FCS (Sigma, #F7524), seeded in a black 96-well assay plate (Corning, #3340), and incubated overnight at 37°C and 5% CO2. CellToxGreen dye (Promega, #G8731), serially diluted bispecific antibodies (0.3nM-1.2pM), and 50,000 purified T cells (target cell / effector cell ratio of 1:10), all diluted in assay medium containing RPMI 1640 w / o phenol red (Gibco, #32404-014), GlutaMAX, and 10% fetal bovine serum, were added to the cells and incubated at 37°C and 5% CO2 for 72 hours. The cells were stained with Tecan Infinite Cytotoxic activity was assessed by measuring the incorporated CellToxGreen fluorescence at 485 nm excitation and 535 nm emission using an F500 instrument. EC was calculated using 4-parameter nonlinear regression analysis in Prism software (GraphPad Software Inc.). 50 value.

[0537] Table 27 summarizes the average IC values ​​of T cell redirected killing of SKOV-3 cells mediated by bispecific antibodies containing different linker combinations 50 Value. Confirm that all bispecific antibodies have dose-dependent killing effects. Compared with the initially disclosed joint combination P (BissIg_21#P), 5 joint combinations lead to enhanced cell killing. For any bispecific antibody tested, no HER2-independent MDA-MB468 cell killing effect was observed (data not shown).

[0538] Figure 6 Exemplary SKOV-3 killing results mediated by bispecific antibodies BissIg_21#2 and BissIg_21#5 comprising the most potent Linker Combination 2 and Linker Combination 5 are shown compared to the initially disclosed Linker Combination P (BissIg_21#P).

[0539] Table 27: T cell redirection to kill HER2-positive SKOV-3 cells

[0540]

[0541] *Average of 4 donors **Average of 6 donors

[0542] Example 3.7: T cell activation in the absence of target cancer cells (high-density PBMC assay)

[0543] The ability of the bispecific antibodies comprising different linker combinations in Example 3 to activate human T cells from human blood samples of three different donors in the absence of target cancer cells was tested. The assay was performed substantially as described in Example 2.5. The bispecific antibodies were tested at final concentrations of 1000nM, 200nM, 40nM, 8nM, 1.6nM and 0.32nM. As a positive control, commercially available murine IgG antibody OKT3 was used. The activation of T cells was assessed by assessing the upregulation of CD69 expression on CD4+ and CD8+ T cells. To this end, PBMCs were stained with CD69, CD4 and CD8 antibodies (Biolegend, #310910 / #300508 / #300928) combined with APC, PE and Pacific Blue, respectively. Antibody staining was measured using a NovoCyte 3000 flow cytometer (Acea Biosciences, Inc.) and analyzed using FlowJo software.

[0544] Shown are the average results of T cell activation experiments obtained from 3 donors. Figure 7 A is CD4+ / CD8-T cells, Figure 7 B is CD4- / CD8+T cells. As expected, for the positive control IgG OKT-3, a strong upregulation of CD69 expression on CD4-positive and CD8-positive T cells can be observed. In the absence of target cells expressing HER2, no activation of CD4+T cells was observed for any of the bispecific antibodies tested, even at the highest tested concentration of 1μM (antibody concentration decreased from left to right). For some of the tested linker combinations, slight donor-dependent CD8+T cell activation can be observed, but only at the highest tested antibody concentration of 1μM. The most obvious activation can be observed for the initially disclosed linker combination P (BissIg_21#P), linker combination 1 (BissIg_21#1), and linker combination 6 (BissIg_21#6).

[0545] Example 3.8: Summary of joint optimization

[0546] Compared to the bispecific antibody containing the initially described linker combination P (BissIg_21#P), all bispecific 2+1 Fab2-Fv-Fc antibodies using the new linker combination in Example 3 showed similar properties in terms of production and binding to CD3.

[0547] However, compared to BissIg_21#P comprising the initially described linker combination P, bispecific antibodies BissIg_21#1, BissIg_21#2, BissIg_21#3, BissIg_21#4 and BissIg_21#5 comprising linker combinations 1, 2, 3, 4 and 5, respectively, showed improved efficacy in T cell-mediated SKOV-3 cell killing and less target-independent T cell activation. However, all bispecific antibodies comprising peptide linkers of the CH1 or Cλ class showed signs of O-glycosylation after mammalian production as determined by mass spectrometry. Only the bispecific antibody BissIg_21#2 comprising linker combination 2 comprising an extended 20-mer peptide linker (G4S)4 (SEQ ID NO: 31) and 20aa-PAPDA (SEQ ID NO: 33) showed no signs of O-glycosylation. Therefore, linker combination 2 was identified as the most preferred linker combination for use in the improved bispecific 2+1 Fab2-Fv-Fc antibody format of Example 3.

[0548] Example 4: Optimized CD3-specific antibody CD3-MAB opt-cc Generation of deimmunized variant antibodies

[0549] Preparation of CD3-MAB of Example 2 opt-cc A deimmunized variant of a human CD3-specific antibody having a VH of SEQ ID: 14 ​​and a VL of SEQ ID NO: 20.

[0550] The antibody is characterized by germline-encoded human framework regions in its VH and VL and germline-encoded LCDR1 and LCDR2 regions. The following examples describe CD3-MAB opt-cc Deimmunization of the non-human germline encoded HCDR1, HCDR2, HCDR3 and LCDR3 regions.

[0551] Example 4.1: CD3-MAB opt-cc Identification of (potential) T-cell epitopes, H-lines and hotspots in the CDR regions of

[0552] In silico T cell epitope screening tools (Lonza, The Epibase TM , Epibase version: v3.0) analysis of CD3-mAb opt-cc The present invention provides a method for screening potential T cell epitopes, H-lines and hot spots in the amino acid sequences of VH (SEQ ID: 14) and VL (SEQ ID NO: 20). The basic computational procedure is described in WO 2003 / 105058 (incorporated herein in its entirety). The screening tool can be used to identify potential T cell epitopes in biotherapeutic proteins (e.g., antibodies). The tool uses the structural features of the HLA receptors and the experimentally determined binding affinity to predict potential peptide / HLA binding, which is a prerequisite for T cell activation.

[0553] For analysis, the entire VH or VL sequence was split into overlapping 10-mer peptides (referred to herein as "analyzed 10-mer peptides"), each peptide shifted by one amino acid. Potential peptide / HLA binding of each 10-mer peptide was determined for HLA class II isotypes of the major Caucasian DRB1 allele. Human antibody germline coding sequence regions were excluded from the analysis.

[0554] Epibase TM Analyze the results

[0555] The results of the computer "search" process showed that CD3-MAB opt-cc There are 6 hot spots in the HCDR1, HCDR2, and HCDR3 regions of CD3-MAB opt-cc There is a hotspot in the LCDR3 region of the . Hotspots reflect the accumulation of adjacent T cell epitopes. Such hotspots are based on Figure 8 and Figure 8 The hotspots were identified using the "4 over 3" algorithm detailed in , and require that at least 4 isoforms of the DRB1 allele bind to at least two of the three consecutively analyzed 10-mer peptides with medium (M) or strong (S) affinity. In addition, at most one 10-mer peptide that has not been identified as a T-cell epitope can be part of a hotspot. Therefore, not every identified T-cell epitope must be part of a hotspot (see e.g. Figure 4 On the other hand, peptides that are not identified as T cell epitopes may still be part of the hotspot (see e.g. Figure 4 Each 10-mer peptide that is part of a hotspot is defined as an H-line. The absolute risk score for a hotspot can be calculated as the sum of the risk scores determined for each T cell epitope within the hotspot and is provided as an "H-score".

[0556] Tables 28 and 29 provide CD3-MAB opt-cc Summary of the overall determined immunogenicity risk parameters for VH and VL. Since the LCDR1+2 regions are germline encoded sequences, no hotspots were assigned to these regions.

[0557] Table 28: Antibody CD3-MAB opt-cc Epibase screening results of VH

[0558] Absolute rating 652.5 Absolute hot spot 6 Absolute H-Rating 580 Absolute H-Line 25 Absolute T cell epitope 23

[0559] Table 29: Epibase screening results of VL of CD3-MABopt-cc

[0560] Absolute rating 188,8 Absolute hot spot 1 Absolute H-Rating 188,8 Absolute H-Line 7 Absolute T cell epitope 6

[0561] Figure 8 CD3-mAb opt-ccExemplary detailed screening analysis of the HCDR3 region of Figure 8 Legend for Figure 1). In summary, for the HCDR3 region, 2 hotspots were identified, including 7 T cell epitopes and 9 H-lines, with an H-score of 236. For the HCDR2 region, 3 hotspots were identified, including 10 T cell epitopes and 12 H-lines, with an H-score of 254.1. For the HCDR1 region, 1 hotspot was identified, including 3 T cell epitopes and 4 H-lines, with an H-score of 89.9. For the LCDR3 region, 1 hotspot was identified, including 6 T cell epitopes and 7 H-lines, with an H-score of 188.8.

[0562] Example 4.2: Generation of Antibody CD3-MAB by Single Amino Acid Substitutions in CDR Regions opt-cc Deimmunized variant VH and VL sequences

[0563] In order to opt-cc Epibase was performed in silico to remove or reduce previously identified hot spots, T cell epitopes and / or H-lines in the CDR regions of TM Mutation analysis, including CD3-mAb opt-cc Each amino acid position in VH and VL is actually replaced / randomized to each naturally occurring amino acid residue except cysteine, proline and histidine. Amino acid substitution preferably results in a reduction of T cell epitopes within the identified hot spots by >= 2, and conservative amino acid substitutions are preferably allowed, such as selecting amino acids with similar charge or polarity, which are selected for gene synthesis of deimmunized variant VH and VL antibody sequences. In addition, care is taken not to introduce potential post-translational modification sites ("PTM motifs") into the CDR regions.

[0564] Fig. 9 Depicted are the CD3-mAbs compared to the unmodified parental sequence. opt-cc The number of T cell epitopes affected by a single amino acid substitution at each HCDR3 position ( Figure 4 Left) and the corresponding absolute risk score ( Figure 4 right). Fig.10 Depicted are the effects of preferred single amino acid substitutions on the number of T-cell epitopes for 24 actually produced and characterized bispecific antibodies (described below) comprising either VH or VL single point mutation variants.

[0565] In total, 92 CD3-mAbs were generated by a PCR-based mutagenesis strategy opt-ccPhysical VH or VL single-site variants. Briefly, linear DNA fragments were generated by PCR with appropriate oligonucleotides containing preferred mutations and homologous overlapping sequences and subsequently cloned into the corresponding mammalian bispecific antibody expression vector encoding a bispecific 2+1 Fab2-Fv-Fc antibody format specific for HER2 and CD3 as described in Example 3. VH variants and CD3-MAB opt-cc The parent unmodified VL (SEQ ID NO: 20) was combined with the VL variants and CD3-MAB opt-cc The generation of bispecific antibodies was as described in Example 3.

[0566] Overall, approximately 50% of bispecific antibodies could be produced with an acceptable monomer content >85% (see Table 30). Fig.10 The yields and final monomer contents of bispecific antibody preparations containing the 24 preferred single-site variants described above are summarized

[0567] Table 30: Summary of generated bispecific antibodies comprising CDR single-site variants of CD3-MABopt-cc, with monomer content >85% as determined by analytical size exclusion chromatography.

[0568]

[0569] Surprisingly, it was found that amino acid exchanges at specific CDR positions (even conservative ones) had a strong negative impact on the manufacturability of the bispecific antibodies, i.e., resulted in an increased tendency to aggregate. Table 31 describes the CD3-MAB opt-cc The amino acid positions substituted within the CDRs of the described bispecific antibodies were significantly reduced in the monomer content of the corresponding generated bispecific antibodies.

[0570] Table 31: CD3-MAB opt-cc The amino acid positions were substituted within the CDRs, which resulted in a significant increase in aggregate formation of the bispecific antibody preparation.

[0571]

[0572] Example 4.3: ELISA binding

[0573] 46 bispecific single-site variant antibodies generated according to Example 4.2, with a monomer content of >85%, characterized by ELISA binding to human CD3ε antigen (hCD3e(22-118)_F-chLys_avi (SEQ ID NO:43), were coated on Maxisorp plates (Nunc, #460518). The final antibody concentrations were set to 50, 10, 2, and 0.4 nM, respectively. Bound antibodies were detected using an alkaline phosphatase-conjugated detection antibody against human F(ab)'2 fragment (Jackson Immuno Research, #109-055-097). EC was calculated using a 4-parameter nonlinear regression analysis in Prism software (GraphPad Software Inc.) 50 value.

[0574] Fig.10 The ELISA EC of 24 bispecific single-site variant antibodies against human CD3ε antigen was summarized. 50 Estimated values ​​revealed that CD3-mAb opt-cc Similar or even better binding to CD3 compared to 50 Estimate + sum of signal above background for all tested antibody concentrations).

[0575] Example 4.4: Determination of K by Antibody Capture Device D

[0576] Affinity determination of bispecific single-point variant antibodies was performed by determining kinetic rate constants, as previously described in Example 3.4. Different bispecific antibody samples diluted in assay buffer (1% BPBS + 0.05% Tween20) were captured on IgG-specific BLI sensors with a loading level of approximately 2 nm. For analysis, human CD3ε antigen hCD3e (22-118) _F-chLys_avi (SEQ ID NO: 43) was diluted with assay buffer to concentrations ranging from 200 nM to 3.1 nM. A blank sample containing assay buffer was included for reference, i.e., to correct for the dissociation of the capture antibody. A binding phase of 180 seconds was recorded, followed by a dissociation phase of 300 seconds. The sensor graph was fitted using Octet data analysis software 10.0 (FortéBio, Sartorius AG) to determine k on and k off rate constants (using a 1:1 binding model), which are used to calculate K D .

[0577] Fig.10 The K values ​​of 24 preferred bispecific single-site variant antibodies against human CD3ε antigen were summarized. D These variants showed similarity to the parent antibody CD3-MABopt-cc Comparable monovalent affinities in the single-digit nanomolar range.

[0578] Example 4.5: CD3-MAB opt-cc Summary of Deimmunized Single-Site Variants

[0579] Fig.10 The biophysical and functional characteristics of 24 preferred bispecific single site variant antibodies (5 LCDR3 variants and 19 HCDR variants) selected based on their manufacturability and ELISA binding are summarized. All variants showed reduced immunogenicity risk as measured by reduction in T cell epitopes, H-lines, absolute scores and H-scores, but retained the parental CD3-mAb when tested in the bispecific antibody format described herein. opt-cc biophysical and functional properties.

[0580] 14 of the 19 single-site variants (listed in Table 32) were derived from the combined T cell epitope Epibase TM The selected ones in the analysis were described below (see Example 4.6) because only 5 of the 19 single-point variants could be determined for hotspot reduction. Table 32 summarizes the impact of each of the 14 selected single-point variants on the immunogenicity risk parameters compared to the parameters of the parent antibody. It is noteworthy that only the substitutions at HCDR2 position V61 and HCDR1 position Y33 resulted in hotspot reduction.

[0581] For CD3-mAb opt-cc The LCDR3 variant S95E was selected as the only preferred VL variant to be used with any other VH variants. When tested in the bispecific antibody format of Example 4.2, this single-site LCDR3 variant resulted in a reduction of 4 H-lines in LCDR3 and showed comparable activity to CD3-MAB. opt-cc The parental antibody VH has similar functional and biophysical properties.

[0582] Table 32: Targeting CD3-MAB opt-cc Epibase of preferred HCDR single-site variants of VH TM Summary of T cell epitope screening

[0583]

[0584] Example 4.6 Generation of Deimmunized Sequences by Combining Amino Acid Substitution Variants ("Combinatorial Variants")

[0585] To further reduce CD3-mAb opt-cc Epibase in silico analysis was performed to identify potential T cell epitopes and other immunogenicity risk parameters in the VH-CDR region of TMMutational analysis in which each of the 14 preferred HCDR single-point variants previously identified in Table 32 were virtually combined with each other, including the CD3-mAb at each position opt-cc Therefore, 251 new combinatorial VH-CDR sequence variants (including double, triple and quadruple mutations) were screened for potential T cell epitopes.

[0586] Epibase of combined mutation variants TM Screening analysis results

[0587] Fig.11 Depict CD3-mAb opt-cc Example results of the effects of 54 combined amino acid substitutions in the VH_HCDR1-3 region of CD3-MAB on different immunogenicity risk parameters, resulting in a maximum reduction of 3 hotspots. The first row of the table shows the effects of 54 combined amino acid substitutions in the VH_HCDR1-3 region of CD3-MAB on different immunogenicity risk parameters. opt-cc Risk parameters for VH of (denoted as "wt (parental)"): absolute score, hot spots, absolute H-score and absolute H-line.

[0588] Surprisingly, the key combinatorial variants that reduced hotspots, absolute H-lines, and absolute H-scores could be assigned to the mutational combination of Y33W (HCDR1) + wt Y56 (HCDR2) + V61D / E / or G (HCDR2).

[0589] All 54 VH combinatorial variants (resulting in 3 fewer hotspots) and 40 additional variant combinations (resulting in 2 fewer hotspots (not shown) and showing the strongest reduction in H-lines and absolute scores) were selected for cloning and production in bispecific antibody format as described in Example 3. To this end, each of the 54 combinatorial VH variants was expressed with a VL variant comprising LCDR3 variant S95E (SEQ ID NO: 21). 25 / 94 generated bispecific combinatorial variant antibodies showed a monomer content of >85%. Fig.12 The monomer content of 33 preferred bispecific combination variant antibody preparations determined by analytical size exclusion chromatography is summarized.

[0590] Example 4.7: ELISA binding of bispecific antibodies to recombinant human CD3ε.

[0591] All 94 bispecific combinatorial variant antibodies generated in Example 4.6 were tested for ELISA binding to the recombinant CD3 epsilon antigen as previously described in Example 4.3. opt-cc Compared with the control group, 46 bispecific combination variant antibodies showed better binding to CD3ε, EC 50 Value <30nM. Fig.12 Summary of ELISA EC for 33 preferred bispecific combination variants assayed against human CD3ε antigen 50 value.

[0592] Example 4.8: Determination of K by Antibody Capture Device D

[0593] As previously described in Example 4.4, affinity was determined by determining the kinetic rate constants of the 46 bispecific combination variants in Example 4.6, which showed better ELISA binding to CD3 (Example 4.7). Overall, the bispecific combination variant antibodies showed monovalent affinities for CD3ε in the mid-single to low double nanomolar range. opt-cc (K D Compared with the bispecific antibody with 5% dUTP (0.1% dUTP = 5 nM), no improvement in binding to CD3 was achieved. Fig.12 The K values ​​of 33 preferred bispecific combination variant antibodies against human CD3ε antigen were summarized. D These variants show K D The values ​​were in the range of 5–11 nM, which was comparable to those of the parental antibody CD3-MAB opt-cc The affinities determined for the corresponding bispecific antibodies were comparable.

[0594] Example 4.9 Jurkat NFAT reporter gene cell assay

[0595] The Jurkat NFAT reporter cell assay was performed to evaluate the functional activity of the 46 bispecific combination variant antibodies specific for HER2 and CD3 in Example 4.8. Jurkat cells (ATCC #TIB-152) stably transfected with the NFAT reporter construct were used as surrogate effector cells. As tumor target cells, HER2-positive human SKOV-3 ( HTB-77) tumor cell line. The assay was performed as described in Example 2.3 above. The bispecific antibodies were serially diluted to a final assay concentration range of 50 nM to 0.5 nM (4 dilution steps).

[0596] Most of the bispecific combinatorial variant antibodies induced luciferase activity in the presence of SKOV-3 cells. 50 None of the tested bispecific antibodies showed superiority over the parental antibody CD3-MAB in terms of luciferase activity and maximum luciferase activity levels. opt-cc The activity of the bispecific antibody.

[0597] Fig.12 The RGA results for 33 preferred bispecific combination variant antibodies are summarized. The results are provided as signal above background at the two tested antibody concentrations, and the antibodies are classified accordingly. The upper row of the table provides the parent bispecific antibody CD3-MAB opt-ccThe RGA results showed that the signal intensity of this antibody was the highest at antibody concentrations of 50 nM and 0.5 nM. Overall, it can be inferred that there is a positive correlation between activity in RGA and binding affinity to CD3.

[0598] Example 4.10 Exploratory scale production

[0599] 33 preferred bispecific combination variants of Example 4.9 were selected for larger scale production. Selection criteria included K for human CD3 epsilon. D values ​​(Example 4.8), functional activity in reporter gene assays (Example 4.9) and monomer content after small-scale production (Example 4.6).

[0600] Eukaryotic HEK293-6E cells were transfected with mammalian expression vector DNA encoding the heavy and light chains of the bispecific antibody. Cell culture supernatants were harvested on day 6 post-transfection and subjected to standard Protein A affinity chromatography (MabSelect SURE│GE Healthcare). The buffer was exchanged to 1x Dulbcecco's PBS (pH 7.2│Invitrogen) and the samples were sterile filtered (0.2 μm pore size). The protein concentration and purity of the bispecific antibody were determined as described previously.

[0601] Fig.12 The percentage of monomer content of 33 bispecific combination variant antibody preparations produced was summarized. Fifteen of these preparations showed monomer antibody content exceeding 90%.

[0602] Example 4.11: Selection of the most appropriate combination of variant CD3-specific antibodies

[0603] The LCDR3 region and HCDR1-3 region of the CD3-specific antibody CD3-MABopt-cc were deimmunized in parallel, resulting in the identification of 5 preferred deimmunized VH / VL variants. These variants appeared in the 10 best performing bispecific antibodies in each assay of Example 4 above, and were therefore further characterized in the T cell-mediated cytotoxicity assay (Example 4.12) and characterized for their potential to induce T cell activation in the absence of target cells (Example 4.13).

[0604] The above five kinds of CD3-specific antibodies to be immune are represented herein as: CD3-MABdeimm_1, CD3-MABdeimm_2, CD3-MABdeimm_3, CD3-MABdeimm_4 and CD3-MABdeimm_5. Table 7 provides the VH, VL and CDR sequences of each of the five kinds of immune antibodies. The corresponding bispecific antibodies containing the five kinds of immune antibodies are represented herein as: BissIg_21#CD3-MABdeimm_1, BissIg_21#CD3-MABdeimm_2, BissIg_21#CD3-MABdeimm_3, BissIg_21#CD3-MABdeimm_4 and BissIg_21#CD3-MABdeimm_5. Table 14 lists the summary of the individual polypeptides that form the bispecific antibodies prepared according to Example 4. Table 29 provides a summary of the biophysical and functional properties and immunogenicity risk parameters of these five deimmunized CD3-specific antibodies and the corresponding bispecific antibodies.

[0605] Example 4.12: Reprogramming mediated by a bispecific antibody comprising five preferred deimmunized CD3-specific antibodies T cell cytotoxicity.

[0606] The bispecific combination variant antibodies BissIg_21#CD3-MABdeimm_1, BissIg_21#CD3-MABdeimm_2, BissIg_21#CD3-MABdeimm_3, BissIg_21#CD3-MABdeimm_4 and BissIg_21#CD3-MABdeimm_5 were tested for their potential to induce T cell-mediated tumor cell killing after binding to CD3 and HER2. The method was performed as described in Example 3.6. As target cells, 5,000 HER2-expressing SKOV-3 cells were used, resulting in a target cell / effector cell ratio of 1:10.

[0607] Table 33 summarizes the IC values ​​for T cell-mediated killing of all 5 tested bispecific combination variant antibodies. 50 It was confirmed that all five bispecific antibodies had the ability to kill SKOV-3 cells that highly expressed HER2 in a concentration-dependent manner, which was comparable to the bispecific antibody containing the parent antibody CD3-MABopt-cc. Fig.13 Depicted are exemplary SKOV-3 killing results of T cells obtained from one donor and the reference parent antibody CD3-MABopt-cc (BissIg_21#CD3-MABopt-cc) and the most preferred combination variant antibody CD3-MABdeimm_3 (BissIg_21#CD3-MABdeimm_3).

[0608] Example 4.13: T cell activation by bispecific antibodies in the absence of target cancer cells (high-density PBMC assay) Certainly)

[0609] In order to evaluate the safety of de-immunized CD3-specific antibodies, the ability of 5 corresponding bispecific combination variant antibodies BissIg_21#CD3-MABdeimm_1 (CD3-MABdeimm_1), BissIg_21#CD3-MABdeimm_2 (CD3-MABdeimm_2), BissIg_21#CD3-MABdeimm_3 (CD3-MABdeimm_3), BissIg_21#CD3-MABdeimm_4 (CD3-MABdeimm_4) and BissIg_21#CD3-MABdeimm_5 (CD3-MABdeimm_5) to activate human T cells in the absence of target cancer cells was tested. The assay was performed as described in the previous embodiment 3.7. Human blood samples were taken from two different donors. The activation of T cells was evaluated by evaluating the upregulation of CD69 expression on CD4-positive or CD8-positive T cells.

[0610] Table 33 qualitatively summarizes the T cell activation potential of 5 bispecific combination variant antibodies. In the absence of target cells expressing HER2, no T cell activation was observed for any bispecific combination variant antibody, even at the highest tested antibody concentration. At higher tested concentrations, donor-dependent T cell activation of the bispecific antibody BissIg_21#CD3-MABopt-cc containing the parent antibody CD3-MABopt-cc can be observed. The positive control OKT-3 strongly induced CD69 expression of CD4+ and CD8+ T cells at an IgG concentration of 20 nM, ranging from 76-78%. Fig.14 Exemplary results of T cell activation experiments from one donor are shown. Fig.14 A describes the activation results of CD4+ / CD8- T cells. Fig.14 B shows the activation results of CD4- / CD8+ T cells. These results clearly demonstrate the remarkable safety of the deimmunized human CD3-specific antibodies of the present disclosure.

[0611] Example 4.14: Summary of Deimmunized Combination Variants:

[0612] The present invention provides for the first time a method for CDR deimmunization of fully human antibodies with CD3 specificity. Table 33 provides an overview of the functional and biophysical properties of the five preferred deimmunized variants CD3-MABdeimm_1, CD3-MABdeimm_2, CD3-MABdeimm_3, CD3-MABdeimm_4 and CD3-MABdeimm_5 identified in Example 2 and their parent human CD3-specific antibody CD3-MABopt-cc. deimmun_3 It was identified as the most preferred deimmunized CD3-specific antibody of the present invention. The CDR engineering of the parent antibody CD3-MABopt-cc resulted in a total reduction of 2 hotspots in the HCDR2 region and a total reduction of 1 hotspot in the LCDR3 region of the antibody. In addition, a significant reduction in T cell epitopes, H-lines, absolute risk scores and absolute H-scores could be achieved. Therefore, CD3-MAB deimmun_3 Once administered, the risk of inducing immunogenic responses in humans is significantly reduced, which is a very critical aspect in T cell engagement therapies. deimmun_3 This remarkable safety profile of CD3-MABopt-cc was further enhanced by its inability to induce T cell activation in the absence of target cells. Notably, CDR engineering did not result in a loss of specificity, functional activity, and manufacturability compared to the parent antibody CD3-MABopt-cc. This is even more striking because CDR engineering affected the HCDR3 region of CD3-MABopt-cc, which is the most relevant CDR for antigen recognition.

[0613] Table 33: Summary of functional and biophysical properties of 5 preferred deimmunized combinatorial variant antibodies derived from the parent antibody CD3-MABopt-cc according to the invention.

[0614]

[0615]

Claims

1. An isolated human antibody or antigen-binding fragment thereof specific for cluster of differentiation 3 (CD3), the human antibody or antigen-binding fragment thereof comprising i. The heavy chain variable region (VH), which comprises (a) a heavy chain complementarity determining region (HCDR) 1 comprising the amino acid sequence GFSFGSHYMS (SEQ ID NO: 1), (b) a HCDR2 comprising the amino acid sequence NINQIGYSSYYVESVKG (SEQ ID NO: 2), NINQIGYSSYYGESVKG (SEQ ID NO: 3) or NINQIGYSSYYEESVKG (SEQ ID NO: 4), and (c) a HCDR3 comprising the amino acid sequence GYSAEFAHRSGLDV (SEQ ID NO: 5), GYSDEFATRSGLDV (SEQ ID NO: 6), GYSEEFAHRSGLDV (SEQ ID NO: 7), GYSDEFAKRSGLDV (SEQ ID NO: 8) or GYSDEFAHRSGLDV (SEQ ID NO: 9), and ii. a variable light chain region (VL), which comprises (a) a light chain complementary determining region (LCDR) 1 comprising the amino acid sequence SGSSSNIGSNYVY (SEQ ID NO: 10), (b) LCDR2 comprising the amino acid sequence RNNQRPS (SEQ ID NO: 11), and (c) LCDR3 comprising the amino acid sequence AGWSRSLHGAV (SEQ ID NO: 12) or AGWSRELHGAV (SEQ ID NO: 13).

2. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof cross-reactively binds to cynomolgus monkey CD3.

3. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof is a deimmunized antibody.

4. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof has a reduced risk of eliciting an immune response in humans.

5. The antibody or antigen-binding fragment thereof of any of the preceding claims, wherein VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19, and / or VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence of SEQ ID NO: 20 or SEQ ID NO:

21.

6. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein VH and VL are selected from: i. a VH comprising the amino acid sequence of SEQ ID NO: 14 and a VL comprising the amino acid sequence of SEQ ID NO: 20, ii. a VH comprising the amino acid sequence of SEQ ID NO: 15 and a VL comprising the amino acid sequence of SEQ ID NO: 21, iii. a VH comprising the amino acid sequence of SEQ ID NO: 16 and a VL comprising the amino acid sequence of SEQ ID NO: 21, iv. a VH comprising the amino acid sequence of SEQ ID NO: 17 and a VL comprising the amino acid sequence of SEQ ID NO: 21, v. a VH comprising the amino acid sequence of SEQ ID NO: 18 and a VL comprising the amino acid sequence of SEQ ID NO: 21, and vi. VH comprising the amino acid sequence of SEQ ID NO:19 and VL comprising the amino acid sequence of SEQ ID NO:

21.

7. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof is a recombinant antibody or antigen-binding fragment thereof.

8. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.

9. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antigen-binding fragment is Fab, Fab', (Fab') 2 , Fv or scFv.

10. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody is a full-length antibody.

11. A bispecific antibody comprising an antigen-binding fragment of the antibody according to any one of the preceding claims and a second antigen-binding fragment of the antibody that binds to a different target antigen than the first antigen-binding fragment. 12 . The bispecific antibody according to claim 11 , wherein the second antigen-binding fragment binds to a cell surface antigen, in particular to a tumor-associated cell surface antigen.

13. The antibody or antigen-binding fragment thereof according to any one of claims 1-10 or the bispecific antibody according to claims 11-12, comprising an Fc region comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.

14. A nucleic acid composition comprising a nucleic acid sequence or a plurality of nucleic acid sequences encoding the antibody or antigen-binding fragment thereof according to claims 1-10 and 13 or the bispecific antibody according to claims 11-13.

15. A vector composition comprising one or more vectors comprising the nucleic acid sequence or sequences according to claim 14.

16. A host cell comprising the vector composition according to claim 15.

17. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to claims 1-10 and 13 or the bispecific antibody according to claims 11-13 and a pharmaceutically acceptable carrier or excipient.

18. The antibody or antigen-binding fragment thereof according to claims 1-10 and 13 or the bispecific antibody according to claims 11-13 or the pharmaceutical composition according to claim 17 for use as a medicament.